<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">36158</article-id><article-id pub-id-type="doi">10.7554/eLife.36158</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Glutathione de novo synthesis but not recycling process coordinates with glutamine catabolism to control redox homeostasis and directs murine T cell differentiation</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-108034"><name><surname>Lian</surname><given-names>Gaojian</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-108035"><name><surname>Gnanaprakasam</surname><given-names>JN Rashida</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9086-0949</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-108036"><name><surname>Wang</surname><given-names>Tingting</given-names></name><email>Tingting.Wang@nationwidechildrens.org</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-108037"><name><surname>Wu</surname><given-names>Ruohan</given-names></name><email>Ruohan.Wu@nationwidechildrens.org</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-108038"><name><surname>Chen</surname><given-names>Xuyong</given-names></name><email>Xuyong.Chen@nationwidechildrens.org</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-108039"><name><surname>Liu</surname><given-names>Lingling</given-names></name><email>Lingling.Liu@nationwidechildrens.org</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-108040"><name><surname>Shen</surname><given-names>Yuqing</given-names></name><email>yuqingshenseu@hotmail.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-108041"><name><surname>Yang</surname><given-names>Mao</given-names></name><email>Mao.Yang@STJUDE.ORG</email><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-108042"><name><surname>Yang</surname><given-names>Jun</given-names></name><email>Jun.Yang2@STJUDE.ORG</email><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-108043"><name><surname>Chen</surname><given-names>Ying</given-names></name><email>ying.chen@yale.edu</email><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-108044"><name><surname>Vasiliou</surname><given-names>Vasilis</given-names></name><email>vasilis.vasiliou@yale.edu</email><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-116754"><name><surname>Cassel</surname><given-names>Teresa A</given-names></name><email>terricassel@gmail.com</email><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-14635"><name><surname>Green</surname><given-names>Douglas R</given-names></name><email>Douglas.Green@stjude.org</email><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-108045"><name><surname>Liu</surname><given-names>Yusen</given-names></name><email>Yusen.Liu@nationwidechildrens.org</email><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-116755"><name><surname>Fan</surname><given-names>Teresa WM</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-107485"><name><surname>Wang</surname><given-names>Ruoning</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-9798-8032</contrib-id><email>ruoning.wang@nationwidechildrens.org</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund10"/><xref ref-type="other" rid="fund11"/><xref ref-type="other" rid="fund12"/><xref ref-type="other" rid="fund13"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Center for Childhood Cancer and Blood Diseases, Hematology, Oncology and BM</institution><institution>The Research Institute at Nationwide Children's Hospital, Ohio State University</institution><addr-line><named-content content-type="city">Columbus</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Medical Research Center</institution><institution>University of South China</institution><addr-line><named-content content-type="city">Hengyang, Hunan Province</named-content></addr-line><country>China</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">Department of Immunology</institution><institution>St. Jude Children’s Research Hospital</institution><addr-line><named-content content-type="city">Memphis</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution content-type="dept">Department of Surgery</institution><institution>St. Jude Children’s Research Hospital</institution><addr-line><named-content content-type="city">Memphis</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution content-type="dept">Department of Environmental Health Sciences, Yale School of Public Health</institution><institution>Yale University</institution><addr-line><named-content content-type="city">New Haven</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution content-type="dept">Department of Toxicology and Cancer Biology</institution><institution>University of Kentucky</institution><addr-line><named-content content-type="city">Lexington</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution content-type="dept">Markey Cancer Center</institution><institution>University of Kentucky</institution><addr-line><named-content content-type="city">Lexington</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution content-type="dept">Center for Environmental and Systems Biochemistry</institution><institution>University of Kentucky</institution><addr-line><named-content content-type="city">Lexington</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution content-type="dept">Center for Perinatal Research</institution><institution>The Research Institute at Nationwide Children's Hospital, Ohio State University</institution><addr-line><named-content content-type="city">Columbus</named-content></addr-line><country>Ohio, United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Dustin</surname><given-names>Michael L</given-names></name><role>Reviewing Editor</role><aff><institution>University of Oxford</institution><country>United Kingdom</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Taniguchi</surname><given-names>Tadatsugu</given-names></name><role>Senior Editor</role><aff><institution>Institute of Industrial Science, The University of Tokyo</institution><country>Japan</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>10</day><month>09</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>7</volume><elocation-id>e36158</elocation-id><history><date date-type="received" iso-8601-date="2018-02-23"><day>23</day><month>02</month><year>2018</year></date><date date-type="accepted" iso-8601-date="2018-09-09"><day>09</day><month>09</month><year>2018</year></date></history><permissions><copyright-statement>© 2018, Lian et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Lian et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-36158-v2.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.36158.001</object-id><p>Upon antigen stimulation, T lymphocytes undergo dramatic changes in metabolism to fulfill the bioenergetic, biosynthetic and redox demands of proliferation and differentiation. Glutathione (GSH) plays an essential role in controlling redox balance and cell fate. While GSH can be recycled from Glutathione disulfide (GSSG), the inhibition of this recycling pathway does not impact GSH content and murine T cell fate. By contrast, the inhibition of the de novo synthesis of GSH, by deleting either the catalytic (Gclc) or the modifier (Gclm) subunit of glutamate–cysteine ligase (Gcl), dampens intracellular GSH, increases ROS, and impact T cell differentiation. Moreover, the inhibition of GSH de novo synthesis dampened the pathological progression of experimental autoimmune encephalomyelitis (EAE). We further reveal that glutamine provides essential precursors for GSH biosynthesis. Our findings suggest that glutamine catabolism fuels de novo synthesis of GSH and directs the lineage choice in T cells.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>T cells</kwd><kwd>ROS</kwd><kwd>glutathione</kwd><kwd>activation</kwd><kwd>differentiation</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004735</institution-id><institution>Natural Science Foundation of Hunan Province</institution></institution-wrap></funding-source><award-id>2018JJ2351</award-id><principal-award-recipient><name><surname>Lian</surname><given-names>Gaojian</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000048</institution-id><institution>American Cancer Society</institution></institution-wrap></funding-source><award-id>130421-RSG-17-071-01-TBG</award-id><principal-award-recipient><name><surname>Yang</surname><given-names>Jun</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R03 CA212802-01A1</award-id><principal-award-recipient><name><surname>Yang</surname><given-names>Jun</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>K01AA025093</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Ying</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R24AA022057</award-id><principal-award-recipient><name><surname>Vasiliou</surname><given-names>Vasilis</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution>American Lebanese and Syrian Associated Charities</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Green</surname><given-names>Douglas R</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R21 AI113930</award-id><principal-award-recipient><name><surname>Liu</surname><given-names>Yusen</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>1P01CA163223-01A1</award-id><principal-award-recipient><name><surname>Fan</surname><given-names>Teresa WM</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000062</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>1U24DK097215-01A1</award-id><principal-award-recipient><name><surname>Fan</surname><given-names>Teresa WM</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R21AI117547</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Ruoning</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000048</institution-id><institution>American Cancer Society</institution></institution-wrap></funding-source><award-id>128436-RSG-15-180-01-LIB</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Ruoning</given-names></name></principal-award-recipient></award-group><award-group id="fund12"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>1R01AI114581</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Ruoning</given-names></name></principal-award-recipient></award-group><award-group id="fund13"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001368</institution-id><institution>V Foundation for Cancer Research</institution></institution-wrap></funding-source><award-id>V2014-001</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Ruoning</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Metabolic reprogramming in suppressing oxidative stress during TH17 cell differentiation.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Glutathione (GSH) is the most abundant antioxidant capable of providing reducing equivalents and it also serves as a versatile nucleophilic cofactor in a wide spectrum of metabolic reactions in aerobic organisms (<xref ref-type="bibr" rid="bib48">Kosower and Kosower, 1978</xref>; <xref ref-type="bibr" rid="bib62">Meister, 1982</xref>). While some cells are capable of employing extracellular GSH, the utilization of extracellular GSH plays a minor role in regulating GSH homeostasis, since the extracellular levels of GSH are normally three orders of magnitude lower than intracellular GSH concentrations, which are usually in the millimolar range (<xref ref-type="bibr" rid="bib48">Kosower and Kosower, 1978</xref>; <xref ref-type="bibr" rid="bib62">Meister, 1982</xref>; <xref ref-type="bibr" rid="bib82">Perrone et al., 2005</xref>; <xref ref-type="bibr" rid="bib37">Hwang et al., 1992</xref>; <xref ref-type="bibr" rid="bib29">Ganguly et al., 2003</xref>; <xref ref-type="bibr" rid="bib5">Bennett et al., 2009</xref>; <xref ref-type="bibr" rid="bib66">Morgan et al., 2011</xref>; <xref ref-type="bibr" rid="bib76">Park et al., 2016</xref>). Hence, cellular GSH content is largely determined by intracellular production through de novo synthesis, a process mediated by two ATP-dependent ligases, glutamate-cysteine ligase (GCL) and glutathione synthase (GS), as well as through regeneration of GSH from GSSG, a process catalyzed by glutathione disulfide reductase (GSR) (<xref ref-type="bibr" rid="bib62">Meister, 1982</xref>; <xref ref-type="bibr" rid="bib54">Lu, 2009</xref>). In the process of de novo synthesis, GCL, a heterodimer of a catalytic subunit (GCLC) and a modifier subunit (GCLM), catalyzes the first and rate-limiting step to form the dipeptide γ-glutamylcysteine (γ-GC) from cysteine and glutamate (<xref ref-type="bibr" rid="bib27">Franklin et al., 2009</xref>; <xref ref-type="bibr" rid="bib10">Chen et al., 2005</xref>). After the initial step, GS catalyzes the formation of GSH by ligating γ-GC with glycine. As such, GSH synthesis is determined by the availability of its constituent amino acids, cysteine, glycine and glutamate, which intersects with glucose and glutamine metabolic pathways and reflects the overall metabolic status in the cell. In particular, glutamine catabolism may coordinate with de novo GSH synthesis by promoting cysteine uptake and providing glutamate, an immediate product of glutamine after deamination (<xref ref-type="bibr" rid="bib3">Altman et al., 2016</xref>; <xref ref-type="bibr" rid="bib35">Hensley et al., 2013</xref>; <xref ref-type="bibr" rid="bib33">Gorrini et al., 2013</xref>). However, it remains unknown the extent to which de novo synthesis versus recycling of GSSG contributes to GSH homeostasis in T cells and how the perturbation of GSH homeostasis impacts T cell differentiation.</p><p>The regulation of metabolic pathways is tightly linked with T cell activation, differentiation, and immune functions (<xref ref-type="bibr" rid="bib108">Wang and Green, 2012</xref>; <xref ref-type="bibr" rid="bib79">Pearce and Pearce, 2013</xref>; <xref ref-type="bibr" rid="bib74">O'Neill et al., 2016</xref>; <xref ref-type="bibr" rid="bib77">Patel and Powell, 2017</xref>; <xref ref-type="bibr" rid="bib57">Ma et al., 2017</xref>; <xref ref-type="bibr" rid="bib9">Buck et al., 2017</xref>; <xref ref-type="bibr" rid="bib117">Zeng and Chi, 2017</xref>; <xref ref-type="bibr" rid="bib25">Finlay and Cantrell, 2011</xref>; <xref ref-type="bibr" rid="bib111">Weinberg et al., 2015</xref>). We and others have shown that activation of T cells leads to a significant enhancement of aerobic glycolysis but a suppression of mitochondria-dependent fatty acid oxidation (FAO) (<xref ref-type="bibr" rid="bib107">Wang et al., 2011</xref>; <xref ref-type="bibr" rid="bib28">Frauwirth et al., 2002</xref>; <xref ref-type="bibr" rid="bib39">Jacobs et al., 2008</xref>; <xref ref-type="bibr" rid="bib95">Shi et al., 2011</xref>). Following the initial growth stage of T cell activation, FAO fuels and drives induced CD4<sup>+</sup> regulatory T (Treg) cell differentiation (<xref ref-type="bibr" rid="bib95">Shi et al., 2011</xref>; <xref ref-type="bibr" rid="bib63">Michalek et al., 2011</xref>). In contrast, a persistent glycolytic program is engaged not only during the initial growth phase of T cell activation but also throughout the differentiation of other CD4<sup>+</sup>T helper (T<sub>H</sub>) cells and CD8<sup>+</sup> cytotoxic T (CTL) cells (<xref ref-type="bibr" rid="bib95">Shi et al., 2011</xref>; <xref ref-type="bibr" rid="bib63">Michalek et al., 2011</xref>; <xref ref-type="bibr" rid="bib26">Finlay et al., 2012</xref>). However, oxygen consumption is also dramatically elevated in active T cells since heightened glutamine catabolism via mitochondria-dependent oxidation following T cell activation fuels oxidative phosphorylation (OXPHOS) by providing α-ketoglutarate (α-KG), an anaplerotic substrate of the tricarboxylic acid cycle (TCA cycle) (<xref ref-type="bibr" rid="bib107">Wang et al., 2011</xref>; <xref ref-type="bibr" rid="bib93">Sena et al., 2013</xref>; <xref ref-type="bibr" rid="bib42">Kamiński et al., 2012</xref>). OXPHOS in mitochondria generates ATP through the electron transport chain (ETC) and also produces reactive oxygen species (ROS) as byproducts, rendering mitochondria a major source of intracellular ROS. Superoxide anion (O<sub>2</sub><sup>•−</sup>), the ‘primary’ ROS derived from mitochondrial ETC, is converted to hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) by spontaneous and enzymatic processes, whereupon H<sub>2</sub>O<sub>2</sub> freely diffuses into cytosol and functions as a redox signaling molecule to elicit a diverse array of cellular responses, the spectrum of which depends on the level of ROS (<xref ref-type="bibr" rid="bib93">Sena et al., 2013</xref>; <xref ref-type="bibr" rid="bib42">Kamiński et al., 2012</xref>; <xref ref-type="bibr" rid="bib70">Murphy, 2009</xref>; <xref ref-type="bibr" rid="bib91">Schieber and Chandel, 2014</xref>). A fine-tuned balance between ROS generation and antioxidant capacity ensures physiological levels of intracellular ROS, which are required for driving essential signaling events to support T cell-mediated immune responses (<xref ref-type="bibr" rid="bib111">Weinberg et al., 2015</xref>; <xref ref-type="bibr" rid="bib71">Murphy and Siegel, 2013</xref>; <xref ref-type="bibr" rid="bib43">Kamiński et al., 2013</xref>; <xref ref-type="bibr" rid="bib96">Simeoni et al., 2016</xref>; <xref ref-type="bibr" rid="bib87">Rashida Gnanaprakasam et al., 2018</xref>). Accordingly, oxidative stress, occurring when ROS generation exceeds the capacity of antioxidants, dampens essential cellular processes and functions of T cells. In innate immune cells, ROS are effector molecules that are capable of directly killing pathogens as well as act as redox signaling molecules that modulate a wide range of innate immune responses (<xref ref-type="bibr" rid="bib91">Schieber and Chandel, 2014</xref>; <xref ref-type="bibr" rid="bib65">Mills et al., 2017</xref>; <xref ref-type="bibr" rid="bib73">Nathan and Cunningham-Bussel, 2013</xref>). Accumulating evidence has shown that ROS production is induced following T cell activation and is required for driving T cell activation and proliferation (<xref ref-type="bibr" rid="bib93">Sena et al., 2013</xref>; <xref ref-type="bibr" rid="bib42">Kamiński et al., 2012</xref>). Also, T<sub>H</sub>17 cells are more sensitive to the damaging effects of ROS than are T<sub>reg</sub> cells (<xref ref-type="bibr" rid="bib30">Gerriets et al., 2015</xref>). A recent study demonstrated a critical role for GSH biosynthesis in fine-tuning this process by maintaining ROS hemostasis and regulating Myc-dependent T cell metabolic reprogramming during T cell activation (<xref ref-type="bibr" rid="bib58">Mak et al., 2017</xref>; <xref ref-type="bibr" rid="bib46">Klein Geltink et al., 2017</xref>). Little information exists, however, on whether and how T cell metabolic programs modulate T cell GSH biosynthesis and ROS homeostasis.</p><p>Here, we report a critical role for de novo GSH synthesis but not recycling of GSSG in modulating ROS homeostasis and T cell differentiation. Heightened glutamine catabolism during T<sub>H</sub>17 differentiation provides glutamate to support de novo GSH synthesis and suppresses oxidative stress. Genetic ablation of de novo synthesis of GSH but not regeneration of GSH from GSSG leads to the augmentation of ROS, dampening T<sub>H</sub>17 differentiation while enhancing T<sub>reg</sub> cell differentiation. Moreover, we found that dimethyl fumarate, an FDA approved drug (BG-12/Tecfidera) for multiple sclerosis, suppresses T<sub>H</sub>17 differentiation by augmenting intracellular ROS. Combining pharmacological and genetic approaches, our studies implicate the GSH-ROS axis as a metabolic checkpoint coordinating glutamine catabolism and T cell signaling to direct T cell differentiation.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>De novo synthesis but not recycling of GSSG is required for producing GSH and suppressing ROS upon TCR stimulation</title><p>T cell activation is associated with enhanced GSH and ROS production (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A and B</xref>) (<xref ref-type="bibr" rid="bib93">Sena et al., 2013</xref>; <xref ref-type="bibr" rid="bib42">Kamiński et al., 2012</xref>; <xref ref-type="bibr" rid="bib58">Mak et al., 2017</xref>). GSH can be regenerated through recycling of glutathione disulfide (GSSG) or synthesized de novo from glutamate, cysteine and glycine (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). GSH regeneration is mediated by glutathione-disulfide reductase (GSR), whereas de novo synthesis is composed of two steps catalyzed by glutamine-cysteine ligase (GCL), a heterodimer of a catalytic subunit (GCLC) and a modulatory subunit (GCLM), and glutathione synthase (GS), respectively (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Thus, we examined the expression of the above key enzymes following T cell activation. Real time quantitative PCR (qPCR) analysis revealed a time-dependent up-regulation of mRNAs encoding these metabolic enzymes in T cells following activation (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>).</p><fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.36158.002</object-id><label>Figure 1.</label><caption><title>De novo synthesis but not recycling of GSSG is required for producing GSH and fine-tuning ROS upon TCR stimulation.</title><p>(<bold>A</bold>) Diagram of GSH biosynthesis, with metabolic pathways highlighted in red and enzymes highlighted in blue. (<bold>B</bold>) Naive CD4<sup>+</sup>T cells from WT and <italic>Gclm</italic> KO (left), or WT (<italic>CD4-Cre-, Gclc<sup>fl/fl</sup></italic>) and <italic>Gclc</italic> KO (<italic>CD4-Cre+, Gclc<sup>fl/fl</sup></italic>, (middle), or WT and <italic>Gsr</italic> KO (right) were activated by plate-bound anti-CD3 plus anti-CD28 for 24 hr, followed by the measurement of GSH levels. (<bold>C</bold>) Naive CD4<sup>+</sup>T cells from WT and <italic>Gclm</italic> KO (left), or WT (<italic>CD4-Cre-, Gclc<sup>fl/fl</sup></italic>) and <italic>Gclc</italic> KO (<italic>CD4-Cre+, Gclc<sup>fl/fl</sup>,</italic> (middle), or WT and <italic>Gsr</italic> KO (right) were activated by plate-bound anti-CD3 plus anti-CD28 for 24 hr, followed by the measurement of ROS levels. Data in <xref ref-type="fig" rid="fig1">Figure 1B–C</xref> are representative of two independent experiments. Data represent the mean ± S.D.</p><p><supplementary-material id="fig1sdata1"><object-id pub-id-type="doi">10.7554/eLife.36158.005</object-id><label>Figure 1—source data 1.</label><caption><title>Source data for B and C.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-36158-fig1-data1-v2.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-36158-fig1-v2"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.36158.003</object-id><label>Figure 1—figure supplement 1.</label><caption><title>TCR stimulation drives GSH and ROS production in T cells.</title><p>(<bold>A–B</bold>) Naive CD4 +T cells from C57BL/6 mice were either cultured in the presence of IL-7 (naive) or activated by plate-bound anti-CD3 and anti-CD28 for 24 hr, followed by measuring intracellular GSH (<bold>A</bold>) and ROS (<bold>B</bold>) by FACS. (<bold>C</bold>) RNAs were isolated from naïve or activated T cells for indicated times, and used for real-time qPCR analyses of indicated genes. Expression levels in naive cells were set to 1. (<bold>D</bold>) The protein levels of Gclm (left) or Gclc (middle) in total T cells from mice with indicated genotypes were determined by western blot. RNAs were isolated from WT or <italic>Gsr</italic> KO T cells and used for real-time qPCR analyses of <italic>Gsr</italic> gene. Expression levels in WT sample were set to 1. Data in Figure A-C are representative of two independent experiments. Data are represented the mean ± S.D.</p><p><supplementary-material id="fig1s1sdata1"><object-id pub-id-type="doi">10.7554/eLife.36158.004</object-id><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Source data for A, B, C and D.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-36158-fig1-figsupp1-data1-v2.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-36158-fig1-figsupp1-v2"/></fig></fig-group><p>To determine the extent to which de novo synthesis contributes to GSH production and redox homeostasis in T cells, we obtained mouse models with genetic deficiencies in GCL. GCLC possesses all the enzymatic activity, while GCLM functions to optimize the catalytic efficiency of the holoenzyme (<xref ref-type="bibr" rid="bib10">Chen et al., 2005</xref>). <italic>Gclm</italic> knockout (<italic>Gclm</italic> KO) mice carry the germ-line deletion of <italic>Gclm</italic>, whereas T cell-specific <italic>Gclc</italic> knockout (T cell<italic>-Gclc</italic> KO) mice, generated by crossing <italic>Gclc-floxed</italic> mice with CD4-Cre mice, carry the <italic>Gclc</italic> deletion exclusively in T cells (<xref ref-type="bibr" rid="bib11">Chen et al., 2007</xref>; <xref ref-type="bibr" rid="bib114">Yang et al., 2002</xref>). Absent expression of GCLM or GCLC in T cells derived from corresponding animals was confirmed by western blot (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>). Next, we examined the intracellular levels of GSH and ROS of T cells that were stimulated with anti-CD3 plus anti-CD28. Deficiency in GCLC (the catalytic subunit) and, to a lesser extent, deficiency in GCLM (modifier subunit) resulted in reduced intracellular content of GSH (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Consistent with this, we observed increased ROS in <italic>Gclc</italic>- and to a lesser extent in <italic>Gclm</italic>-deficient T cells as compared to WT T cells. (<xref ref-type="fig" rid="fig1">Figure 1C</xref>).</p><p>We then sought to determine the extent to which recycling of GSSG contributes to GSH production and redox homeostasis in T cells. For this, we obtained mice carrying germ-line deletion of <italic>Gsr (Gsr<sup>-/-</sup>),</italic> the deletion of which was demonstrated by qPCR (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>) (<xref ref-type="bibr" rid="bib88">Rogers et al., 2004</xref>; <xref ref-type="bibr" rid="bib85">Pretsch, 1999</xref>; <xref ref-type="bibr" rid="bib113">Yan et al., 2012</xref>). However, WT and <italic>Gsr</italic>-deficient T cells displayed comparable GSH and ROS levels (<xref ref-type="fig" rid="fig1">Figure 1B and C</xref>). These results suggested that de novo synthesis of GSH by the metabolic pathway plays an indispensable role in producing GSH and maintaining redox homeostasis during T cell activation.</p></sec><sec id="s2-2"><title>GCLC deficiency but not GCLM or GSR deficiency suppresses T cell activation and proliferation</title><p><italic>Gclm</italic> KO, T cell<italic>-Gclc</italic> KO and <italic>Gsr</italic> KO mice contained comparable numbers and distribution of thymocytes and peripheral CD4<sup>+</sup> and CD8<sup>+</sup> T cells relative to control mice (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A,B,C and D</xref>), indicating a largely undisturbed T cell development and distribution after double positive stage in the absence of GSH recycling pathway or the de novo synthesis pathway. A recent study has showed that Gclc deficiency suppressed T cell activation and proliferation, demonstrating a critical role of GCLC in regulating T cell activation (<xref ref-type="bibr" rid="bib58">Mak et al., 2017</xref>; <xref ref-type="bibr" rid="bib46">Klein Geltink et al., 2017</xref>). This is consistent with the severe GSH depletion and ROS induction in <italic>Gclc</italic>-deficient active T cells (<xref ref-type="fig" rid="fig1">Figure 1B and C</xref>). Our results further suggested that GSR is dispensable and GCLM only play a minor role in modulating GSH production and ROS homeostasis in active T cells (<xref ref-type="fig" rid="fig1">Figure 1B and C</xref>). Next, we sought to differentiate the impact of GSH recycling pathway and de novo synthesis pathway on T cell activation and proliferation. While both Gclc and Gclm deficiency caused a reduction of GSH and induction of ROS, albeit to different degrees (<xref ref-type="fig" rid="fig1">Figure 1B and C</xref>), Gclc but not Gclm deficiency resulted in an impairment of cell viability, appearance of the activation marker CD25, and activation-induced cell proliferation (<xref ref-type="fig" rid="fig2">Figure 2A, B, D, E and G</xref>). This activation and proliferation defect is consistent with a recent study showing that GCLC is required for T cell activation (<xref ref-type="bibr" rid="bib58">Mak et al., 2017</xref>). Previous studies have shown that GSH depletion caused inactivation of glutathione peroxidase 4 (GPX4), and consequentially led to iron-dependent accumulation of lipid peroxidation and a form of cell necrosis referred as ferroptosis (<xref ref-type="bibr" rid="bib99">Stockwell et al., 2017</xref>). Our data suggested that a moderate reduced cell viability in <italic>Gclc</italic>-deficient T cells is likely due to ferroptosis in the context of GSH depletion (<xref ref-type="fig" rid="fig2">Figure 2G</xref>). Our results suggested that a severe depletion of GSH and induction of ROS caused by Gclc deficiency significantly impaired T cell activation and proliferation, however, active T cell could tolerate and cope with a moderate depletion of GSH and induction of ROS caused by Gclm deficiency.</p><fig-group><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.36158.006</object-id><label>Figure 2.</label><caption><title>Severe depletion of GSH by blocking de novo synthesis suppresses T cell activation and proliferation.</title><p>(<bold>A–C</bold>) Naive CD4 +T cells from WT and <italic>Gclm</italic> KO (<bold>A</bold>), or WT (<italic>CD4-Cre-, Gclc<sup>fl/fl</sup></italic>) and <italic>Gclc</italic> KO (<italic>CD4-Cre+, Gclc<sup>fl/fl</sup></italic>) (<bold>B</bold>), or WT and <italic>Gsr</italic> KO (<bold>C</bold>) mice were activated by plate-bound anti-CD3 plus anti-CD28 for 24 hr, followed by cell surface expression of CD25 (upper panel) and CD69 (lower panel). (<bold>D–F</bold>) Cell proliferation of active CD4 +T cells (72 hr) with indicated genotypes was determined by CFSE dilution. (<bold>G</bold>) Naive CD4 +T cells isolated from mice with indicated genotypes were activated by plate-bound anti-CD3 and anti-CD28 for 24 hr. Cell viability was determined by FACS. <xref ref-type="fig" rid="fig2">Figure 2A–G</xref> are representative of three independent experiments.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-36158-fig2-v2"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.36158.007</object-id><label>Figure 2—figure supplement 1.</label><caption><title>Severe depletion of GSH by blocking de novo synthesis suppresses T cell activation and proliferation.</title><p>(<bold>A–C</bold>) Distribution of CD4+ and CD8+ cells in the spleen, lymph nodes or thymus from mice with indicated genotypes were determined by FACS. <xref ref-type="fig" rid="fig2">Figure 2A</xref> -D are representative of two independent experiments (<bold>D</bold>) Bar graph represents the number of T cells calculated from total splenocytes, lymph node cells and thymocytes.</p><p><supplementary-material id="fig2s1sdata1"><object-id pub-id-type="doi">10.7554/eLife.36158.008</object-id><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Source data for A, B, C and D.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-36158-fig2-figsupp1-data1-v2.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-36158-fig2-figsupp1-v2"/></fig></fig-group><p>Consistent with its dispensable role in GSH production in active T cells (<xref ref-type="fig" rid="fig1">Figure 1B and C</xref>), Gsr deficiency did not lead to any impairment of T cell viability, activation marker CD25 and proliferation (<xref ref-type="fig" rid="fig2">Figures 2C, F and G</xref>). Notably, none of the above genetic deficiencies compromised the early activation marker CD69 (<xref ref-type="fig" rid="fig2">Figure 2A–C</xref>). Our results suggest that GSH recycling pathway is dispensable in regulating T cell activation and proliferation. However, the recycling of GSSG to GSH, which is not a parallel pathway for GSH production, plays a critical role in maintaining redox homeostasis when the ratio of GSSG:GSH reaches certain threshold. While our data suggest that Gsr mediated recycling of GSSG is not required for T cell activation and proliferation, we do not have evidence showing that GSSG is significantly accumulated during T cell activation and proliferation. Therefore, a dispensable role of Gsr in maintaining redox homeostasis during T cell activation and proliferation may represent a context-dependent interpretation.</p></sec><sec id="s2-3"><title>Ablation of de novo synthesis but not recycling of GSSG reciprocally alters T<sub>H</sub>17 and iT<sub>reg</sub> cell differentiation</title><p>Following the initial growth stage of cell activation, proliferating CD4<sup>+</sup> T cells can differentiate into various functional subsets including inflammatory T<sub>H</sub>17 and Foxp3-expressing regulatory T cells (T<sub>reg</sub> cells), which are two closely related subsets with distinct functions. Having found a role for de novo synthesis of GSH in modulating GSH and ROS homeostasis during T cell activation, we next assessed the functional requirement for the de novo synthesis pathway of GSH in T cell differentiation. Naive T cells were differentiated under T<sub>H</sub>17 or iT<sub>reg</sub> conditions. As compared to control WT cells, <italic>Gclm</italic> KO cells exhibited reduced IL-17<sup>+</sup> and increased Foxp3<sup>+</sup> cells (<xref ref-type="fig" rid="fig3">Figure 3A and D</xref>). Given that a similar degree of proliferation was observed between WT and <italic>Gclm</italic> KO CD4<sup>+</sup> T cells (<xref ref-type="fig" rid="fig3">Figure 3A and D</xref>), deregulation of cell differentiation in <italic>Gclm</italic> KO was largely independent of cell expansion. To bypass the effect of Gclc deficiency on T cell activation and proliferation (<xref ref-type="fig" rid="fig2">Figure 2B and E</xref>), we generated a mouse model carrying a conditional <italic>Gclc</italic> allele (<italic>Gclc</italic><sup><italic>flox/flox</italic></sup>) and a tamoxifen-induced Cre recombinase (CreERT2) transgene (<xref ref-type="bibr" rid="bib90">Ryan et al., 2000</xref>; <xref ref-type="bibr" rid="bib19">de Luca et al., 2005</xref>), which allowed us to delete <italic>Gclc</italic> flox alleles in an acute manner. For this, we polarized T cells in the absence (WT) or in the presence (KO) of 4-Hydroxytamoxifen (4OHT) (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). As compared with WT cells, acute deletion of Gclc bypassed its required for cell proliferation, as revealed by a comparable CFSE dilution (<xref ref-type="fig" rid="fig3">Figure 3B and E</xref>), but nevertheless resulted in a reduction in the generation of IL-17<sup>+</sup> T cells and an induction in the generation of Foxp3<sup>+</sup> cells. Using this genetic model, we have therefore differentiated the role of GCLC in early T cell activation from its role in driving T<sub>H</sub>17 cell differentiation. In contrast to the effects of ablation of <italic>Gclm</italic> and <italic>Gclc</italic>, <italic>Gsr</italic> KO and WT CD4<sup>+</sup> T cells displayed a similar degree of T<sub>H</sub>17 and iT<sub>reg</sub> differentiation, indicating a dispensable role for recycling GSSG in regulating T cell differentiation (<xref ref-type="fig" rid="fig3">Figure 3C and F</xref>). Next, we tested whether inhibiting ROS generation in T cells that have defects on the de novo synthesis of GSH would restore T<sub>H</sub>17 differentiation. The addition of N-acetyl-L-cysteine (NAC), a reagent often used to scavenge ROS, restored T<sub>H</sub>17 cell differentiation in <italic>Gclc<sup>-/-</sup></italic> T cells (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). While NAC is frequently considered a source of cysteine for synthesis of GSH, while other studies have shown that NAC displayed reducing properties through its thiol-disulfide exchange activity and could directly scavenge free radicals (<xref ref-type="bibr" rid="bib4">Ates et al., 2008</xref>; <xref ref-type="bibr" rid="bib1">Agnihotri and Mishra, 2009</xref>; <xref ref-type="bibr" rid="bib115">Zafarullah et al., 2003</xref>; <xref ref-type="bibr" rid="bib16">Cotgreave, 1997</xref>). Consistent with these, our result suggests that NAC scavenges ROS independently of GSH synthesis (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C and D</xref>) and therefore restores T<sub>H</sub>17 cell differentiation in <italic>Gclc<sup>-/-</sup></italic> T cells. To further evaluate the role of the GSH de novo synthesis pathway in T<sub>H</sub>17-driven EAE in vivo, we immunized mice with the myelin oligodendrocyte glycoprotein (MOG)<sub>35-55</sub> antigen. Genetic ablation of GCLM or GCLC conferred a protection against disease progression (<xref ref-type="fig" rid="fig3">Figure 3G and H</xref>). Furthermore, histological assessment revealed a similar degree of ablation of T cell infiltration in <italic>Gclm</italic> KO and T cell<italic>-Gclc</italic> KO animals compared to WT animals (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>). However, a different degree of ablation of macrophage infiltration in <italic>Gclm</italic> KO and T cell<italic>-Gclc</italic> KO animals compared to WT animals was observed and likely reflected a different level of inflammation in these experimental animals (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>). In contrast to T cell<italic>-Gclc</italic> KO animals, GCLM is also deleted in macrophages in <italic>Gclm</italic> KO animal (a germline KO model). Therefore, we could not exclude the possibility that Gclm deficiency in macrophages might affect macrophage infiltration in our result. Collectively, our studies suggested that de novo synthesis of GSH is required for T<sub>H</sub>17 development in vitro and T<sub>H</sub>17-driven CNS inflammation in vivo.</p><fig-group><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.36158.009</object-id><label>Figure 3.</label><caption><title>Ablation of de novo synthesis but not recycling of GSSG reciprocally alters T<sub>H</sub>17 and iTreg cell differentiation.</title><p>(<bold>A–F</bold>) Naive CD4+ T cells from WT and <italic>Gclm</italic> KO, or WT (<italic>Cre-,) and CreER</italic>+ (<italic>Gclc</italic>-KO- in the presence of 100 nM of 4-hydroxytamoxifen (4OHT)), or WT and <italic>Gsr</italic> KO mice were stained with 4 µm CFSE and differentiated under T<sub>H</sub>17 or iTreg -inducing conditions for 5 days, followed by intracellular staining of IL-17 and Foxp3. (<bold>G–H</bold>) mice with indicated genotypes were immunized with MOG to induce EAE and pathological progressions were scored daily. Data in <xref ref-type="fig" rid="fig4">Figure 4A–H</xref> are representative of two-three independent experiments.</p><p><supplementary-material id="fig3sdata1"><object-id pub-id-type="doi">10.7554/eLife.36158.012</object-id><label>Figure 3—source data 1.</label><caption><title>Source data for G and H.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-36158-fig3-data1-v2.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-36158-fig3-v2"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.36158.010</object-id><label>Figure 3—figure supplement 1.</label><caption><title>Ablation of de novo synthesis but not recycling of GSSG reciprocally alters TH17 and iTreg cell differentiation.</title><p>(<bold>A</bold>) The protein levels of Gclc in cells collected two days following 4OHT treatment were determined by western blot. (<bold>B</bold>) Naïve CD4+ T cells from WT (<italic>CD4-Cre-, Gclcfl/fl</italic>) and <italic>Gclc KO (CD4-Cre+, Gclcfl/fl)</italic> mice were differentiated under TH17-inducing conditions with or without 5 mM N-acetyl cysteine (NAC) for 5 days, followed by intracellular staining of IL-17. (<bold>C</bold>) Naive CD4+ T cells were activated for 24 hr with or without 5 mM NAC, followed by measuring ROS and (<bold>D</bold>) GSH by FACS. (<bold>E</bold>) WT, <italic>Gclm-/-</italic> (KO) and <italic>CD4-Cre, Gclc<sup>fl/fl</sup></italic> (KO) mice were immunized with MOG/CFA. After 20 days, cervical spinal cord sections were analyzed by H and E (bars, 200 μm) and anti-Mac2 and anti-CD3 immunohistochemistry (bars, 50 μm).Data are representative of two independent trials. Data in Figure A-D are representative of two-three independent experiments.</p><p><supplementary-material id="fig3s1sdata1"><object-id pub-id-type="doi">10.7554/eLife.36158.011</object-id><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Source data for C and D.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-36158-fig3-figsupp1-data1-v2.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-36158-fig3-figsupp1-v2"/></fig></fig-group></sec><sec id="s2-4"><title>T<sub>H</sub>17 and iT<sub>reg</sub> cells display different degrees of oxidative stress</title><p>Accumulating evidence has shown that each subset of T cells engages unique metabolic pathways to fulfill its metabolic demands (<xref ref-type="bibr" rid="bib95">Shi et al., 2011</xref>; <xref ref-type="bibr" rid="bib63">Michalek et al., 2011</xref>; <xref ref-type="bibr" rid="bib30">Gerriets et al., 2015</xref>). We envisioned that the differential engagement of metabolic pathways would differentially impact GSH biosynthesis and cellular oxidative stress in T<sub>H</sub>17 and iT<sub>reg</sub> cells. For this, we activated naive CD4<sup>+</sup> T cells under T<sub>H</sub>17 or iT<sub>reg</sub> polarizing conditions in vitro, and examined the intracellular levels of GSH and ROS at day 3 and day 5. T<sub>H</sub>17 cells displayed a higher level of intracellular GSH than iT<sub>reg</sub> cells. In contrast, the level of ROS was lower in T<sub>H</sub>17 cells compared to iT<sub>reg</sub> cells (<xref ref-type="fig" rid="fig4">Figure 4A and B</xref>). In addition, T<sub>H</sub>17 cells displayed a higher level of intracellular GSH and GSSG than iT<sub>reg</sub> cells, as revealed by mass spectrometry (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). A key cellular mechanism in defending against oxidative stress is through activation of nuclear factor erythroid 2-related factor 2 (NRF2), which controls the expression of genes involved in producing, regenerating, and utilizing GSH. NRF2 also controls other antioxidant pathways that regulate thioredoxin (<italic>TXN</italic>), NADPH generation and iron sequestration (<xref ref-type="bibr" rid="bib40">Jaramillo and Zhang, 2013</xref>; <xref ref-type="bibr" rid="bib98">Sporn and Liby, 2012</xref>; <xref ref-type="bibr" rid="bib56">Ma, 2013</xref>; <xref ref-type="bibr" rid="bib68">Motohashi and Yamamoto, 2004</xref>). Consistent with increased levels of GSH and decreased levels of ROS in T<sub>H</sub>17 cells, qPCR analysis revealed a time-dependent up-regulation of mRNAs encoding NRF2 and its target genes, including glucose-6-phosphate dehydrogenase (<italic>G6PD</italic>), <italic>TXN</italic>, thioredoxin reductase 1 (<italic>Txnrd1</italic>), CD44, heme oxygenase-1 (<italic>Hmox1</italic>), NAD(P)H quinone dehydrogenase 1 (<italic>Nqo1</italic>) and glutathione synthetase (<italic>Gss</italic>) (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). These results suggested that T<sub>H</sub>17 cells preferentially maintain a low degree of oxidative stress by a tight regulation of GSH synthesis and ROS homeostasis.</p><fig-group><fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.36158.013</object-id><label>Figure 4.</label><caption><title>T<sub>H</sub>17 cells preferentially maintain higher level of GSH than iT<sub>reg</sub> cells.</title><p>(<bold>A–B</bold>) Naive CD4<sup>+</sup> T cells from C57BL/6 mice were differentiated under iTreg or T<sub>H</sub>17–inducing conditions and cells were collected at indicated times, followed by measuring intracellular GSH (<bold>A</bold>) and ROS (<bold>B</bold>) by FACS. (<bold>C</bold>) Naive CD4<sup>+</sup> T cells from C57BL/6 mice were differentiated under T<sub>H</sub>17 or iT<sub>reg</sub>–inducing conditions for 5 days. The intracellular levels of GSH and GSSG were determined by mass spectrometry. (<bold>D</bold>) Naive CD4<sup>+</sup>T cells from WT and <italic>Gclm</italic> KO (top) or WT (<italic>CD4-Cre-, Gclc<sup>fl/fl</sup></italic>) and <italic>Gclc</italic> KO (<italic>CD4-Cre+, Gclc<sup>fl/fl</sup></italic>, (bottom) were differentiated under T<sub>H</sub>17-inducing conditions for 5 days, followed by the measurement of GSH levels. Data in <xref ref-type="fig" rid="fig4">Figure 4A–D</xref> are representative of three independent experiments. Data represent the mean ± S.D.</p><p><supplementary-material id="fig4sdata1"><object-id pub-id-type="doi">10.7554/eLife.36158.016</object-id><label>Figure 4—source data 1.</label><caption><title>Source data for A, B, C and D.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-36158-fig4-data1-v2.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-36158-fig4-v2"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.36158.014</object-id><label>Figure 4—figure supplement 1.</label><caption><title>De novo synthesis but not recycling of GSSG is required for providing GSH and suppressing ROS during TH17 cell differentiation.</title><p>(<bold>A</bold>) RNAs were isolated from cells differentiated under TH17 or iTreg-inducing conditions for indicated times, and used for real-time qPCR analyses of indicated genes. Expression levels in day 0 were set to 1 (<bold>B–D</bold>) Naive CD4+ T cells from WT and <italic>Gclm</italic> KO, or WT (<italic>CD4-Cre-, Gclc<sup>fl/fl</sup></italic>) and <italic>Gclc</italic> KO (<italic>CD4-Cre+, Gclc<sup>fl/fl</sup></italic><sup>),</sup> or WT and <italic>Gsr</italic> KO mice were differentiated under TH17-inducing conditions for 5 days, followed by measuring ROS by FACS. Data in Figure B-D are representative of two independent experiments. Data represent the mean ±S.D.</p><p><supplementary-material id="fig4s1sdata1"><object-id pub-id-type="doi">10.7554/eLife.36158.015</object-id><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Source data for A, B and C.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-36158-fig4-figsupp1-data1-v2.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-36158-fig4-figsupp1-v2"/></fig></fig-group></sec><sec id="s2-5"><title>De novo synthesis but not recycling of GSSG is required for producing GSH and suppressing ROS during T<sub>H</sub>17 cell differentiation</title><p>The observation that T<sub>H</sub>17 cells displayed increased GSH content and decreased levels of ROS than iT<sub>reg</sub> cells supported the role for GSH in directing T<sub>H</sub>17 cell differentiation (<xref ref-type="fig" rid="fig4">Figure 4A and B</xref>). Next, we sought to determine how two GSH synthetic pathways are engaged and impact on GSH and ROS homeostasis during T<sub>H</sub>17 cell differentiation. For this, we purified naive T cells and differentiated them under T<sub>H</sub>17-polarizing conditions. Deficiency in Gclc and, to a lesser extent, deficiency in Gclm resulted in reduced intracellular content of GSH (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Consistent with this, we observed increased ROS in <italic>Gclc</italic>- and <italic>Gclm</italic>-deficient T cells as compared to WT T cells (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B and C</xref>). By contrast, WT and <italic>Gsr</italic>-deficient T cells displayed comparable GSH sand ROS levels (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D</xref>). These results indicated that the preferential requirement for de novo synthesis of GSH during the initial T cell activation stage is extended to the later T cell differentiation stage. However, the recycling pathway is dispensable in producing GSH and maintaining redox homeostasis during T<sub>H</sub>17 differentiation.</p></sec><sec id="s2-6"><title>Pharmacological augmentation of ROS reciprocally modulates T<sub>H</sub>17 and iT<sub>reg</sub> cell differentiation</title><p>We next asked whether shifting the redox balance towards an oxidative state would perturb T cell differentiation and represent a novel therapeutic strategy for T cell-driven autoimmunity. For this, we activated naive CD4<sup>+</sup> T cells under T<sub>H</sub>17 or iT<sub>reg</sub> polarizing conditions in the presence or absence of H<sub>2</sub>O<sub>2</sub>. Addition of 1 μM H<sub>2</sub>O<sub>2</sub> did not impact cell proliferation but reciprocally reduced T<sub>H</sub>17 and enhanced iT<sub>reg</sub> cell differentiation (<xref ref-type="fig" rid="fig5">Figure 5A and B</xref>), indicating that its effect on differentiation was largely independent of expansion.</p><fig-group><fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.36158.017</object-id><label>Figure 5.</label><caption><title>DMF suppresses T<sub>H</sub>17 differentiation by augmenting ROS generation.</title><p>(<bold>A</bold>) Naive CD4<sup>+</sup> T cells from C57BL/6 mice were differentiated under T<sub>H</sub>17 or iT<sub>reg</sub>-inducing conditions with or without H<sub>2</sub>O<sub>2</sub> (1 µM) for 5 days, followed by intracellular staining of IL-17 and Foxp3. (<bold>B</bold>) Cell proliferation of active CD4<sup>+</sup> T cells (72 hr) with or without H<sub>2</sub>O<sub>2</sub> (1 µM) was determined as CFSE dilution. (<bold>C–D</bold>) Naive CD4<sup>+</sup> T cells from C57BL/6 mice were differentiated under T<sub>H</sub>17-inducing conditions with indicated dose of DMF for 5 days, followed by intracellular staining of IL-17 (<bold>C</bold>) and ROS (<bold>D</bold>). (<bold>E</bold>) Naive CD4<sup>+</sup> T cells from C57BL/6 mice were differentiated under T<sub>H</sub>17-inducing conditions with indicated treatment for 5 days, followed by intracellular staining of IL-17. Data in <xref ref-type="fig" rid="fig5">Figure 5</xref> are representative of two-three independent experiments. Data represent the mean ±S.D.</p><p><supplementary-material id="fig5sdata1"><object-id pub-id-type="doi">10.7554/eLife.36158.019</object-id><label>Figure 5—source data 1.</label><caption><title>Source data for D.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-36158-fig5-data1-v2.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-36158-fig5-v2"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.36158.018</object-id><label>Figure 5—figure supplement 1.</label><caption><title>DMF suppresses T<sub>H</sub>17 differentiation through augmenting ROS generation.</title><p>(<bold>A</bold>) Cell proliferation of active CD4 +T cells (72 hr) with indicated treatments was determined as CFSE dilution (<bold>B</bold>). Naive CD4 +T cells from C57BL/6 mice were differentiated with 5 and 20 µM of DMF under iTreg cell -inducing conditions for 5 days, followed by intracellular staining of Foxp3.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-36158-fig5-figsupp1-v2"/></fig></fig-group><p>The observation of H<sub>2</sub>O<sub>2</sub>-dependent suppression of T<sub>H</sub>17 differentiation prompted us to explore pharmacologic approaches that could augment ROS production in T cells. Dimethyl fumarate (DMF), the key active ingredient of BG-12/TECFIDERA and FUMADERM, has been approved in many countries for treating autoimmune diseases including multiple sclerosis (MS) and psoriasis, both of which are associated with pathogenic T<sub>H</sub>17 cells (<xref ref-type="bibr" rid="bib100">Study group et al., 2014</xref>; <xref ref-type="bibr" rid="bib69">Mrowietz et al., 2007</xref>; <xref ref-type="bibr" rid="bib20">DEFINE Study Investigators et al., 2012</xref>; <xref ref-type="bibr" rid="bib14">CONFIRM Study Investigators et al., 2012</xref>). However, the cellular and molecular mechanisms underlying the therapeutic efficacy of DMF have not been fully elucidated (<xref ref-type="bibr" rid="bib45">Kees, 2013</xref>). Previous studies have implicated DMF in regulating the cellular activities of dendritic cells (DCs), endothelial cells, and neurons through various mechanisms (<xref ref-type="bibr" rid="bib7">Blewett et al., 2016</xref>; <xref ref-type="bibr" rid="bib92">Schulze-Topphoff et al., 2016</xref>; <xref ref-type="bibr" rid="bib110">Wang et al., 2015</xref>; <xref ref-type="bibr" rid="bib12">Chen et al., 2014</xref>; <xref ref-type="bibr" rid="bib81">Peng et al., 2012</xref>; <xref ref-type="bibr" rid="bib52">Linker and Gold, 2013</xref>; <xref ref-type="bibr" rid="bib22">Duffy et al., 1998</xref>; <xref ref-type="bibr" rid="bib32">Gill and Kolson, 2013</xref>). The electrophilic nature of DMF allows it to bind and deplete intracellular GSH (<xref ref-type="bibr" rid="bib118">Zheng et al., 2015</xref>; <xref ref-type="bibr" rid="bib101">Sullivan et al., 2013</xref>). We therefore hypothesized that DMF may induce oxidative stress and affect T cell differentiation. To test this, we activated naive CD4<sup>+</sup> T cells under T<sub>H</sub>17 polarizing conditions in the presence of a range of DMF doses based on previous reports that were designed to investigate the effect of DMF on other cell types (<xref ref-type="bibr" rid="bib81">Peng et al., 2012</xref>; <xref ref-type="bibr" rid="bib52">Linker and Gold, 2013</xref>; <xref ref-type="bibr" rid="bib22">Duffy et al., 1998</xref>). DMF treatment displayed a dosage-dependent suppression of T<sub>H</sub>17 cell differentiation (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Although the addition of 75 μM DMF inhibited T cell proliferation, at the lower dose of DMF used in this study (20–50 μM), we observed minimal inhibitory effects of DMF on cell proliferation (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>), indicating that DMF-mediated suppression on T<sub>H</sub>17 differentiation was largely independent of cell proliferation. Moreover, DMF treatments induced ROS production in T<sub>H</sub>17 cells (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Consistent with the idea that DMF suppresses T<sub>H</sub>17 cell differentiation through the induction of oxidative stress, the addition of N-acetyl-L-cysteine (NAC) restored T<sub>H</sub>17 cell differentiation in the presence of DMF (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). Since H<sub>2</sub>O<sub>2</sub> treatment reciprocally reduced T<sub>H</sub>17 and enhanced iT<sub>reg</sub> cell differentiation (<xref ref-type="fig" rid="fig5">Figure 5A and B</xref>), we next assessed the effect of DMF on iT<sub>reg</sub> cell differentiation. However, the doses of DMF (5 and 20 μM) that could suppress T<sub>H</sub>17 differentiation failed to affect iT<sub>reg</sub> cell differentiation in vitro (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>). As such, our data suggested that DMF may partially exert its immunomodulatory action through the augmentation of oxidative stress and suppressing T<sub>H</sub>17 differentiation. Along with the possibility that DMF-derived fumarate interferes with TCA cycle intermediate metabolite pool, other mechanisms may also contribute to its immunomodulatory functions (<xref ref-type="bibr" rid="bib7">Blewett et al., 2016</xref>; <xref ref-type="bibr" rid="bib92">Schulze-Topphoff et al., 2016</xref>; <xref ref-type="bibr" rid="bib110">Wang et al., 2015</xref>; <xref ref-type="bibr" rid="bib12">Chen et al., 2014</xref>; <xref ref-type="bibr" rid="bib81">Peng et al., 2012</xref>; <xref ref-type="bibr" rid="bib52">Linker and Gold, 2013</xref>; <xref ref-type="bibr" rid="bib22">Duffy et al., 1998</xref>; <xref ref-type="bibr" rid="bib32">Gill and Kolson, 2013</xref>).</p></sec><sec id="s2-7"><title>Glutamate that fuels GSH de novo synthesis is partially derived from glutamine during T<sub>H</sub>17 cell differentiation</title><p>Upon activation, a metabolic reprogramming is required for directing nutrients to meet the bioenergetic, biosynthetic, and redox demands, which prepares T cells for immune defense and regulation. We and others have shown that T cell metabolism changes from relying on FAO and some mitochondria-dependent glucose oxidation to engaging robust aerobic glycolysis and glutaminolysis (<xref ref-type="bibr" rid="bib107">Wang et al., 2011</xref>; <xref ref-type="bibr" rid="bib28">Frauwirth et al., 2002</xref>; <xref ref-type="bibr" rid="bib39">Jacobs et al., 2008</xref>; <xref ref-type="bibr" rid="bib31">Gerriets and Rathmell, 2012</xref>; <xref ref-type="bibr" rid="bib78">Pearce et al., 2009</xref>). Glutamine catabolism not only fuels mitochondrial ATP production through the TCA cycle but also provides metabolic precursors for multiple biosynthetic pathways, including synthesis of glutathione (GSH), an essential cellular antioxidant system to maintain redox homeostasis during T cell activation (<xref ref-type="bibr" rid="bib3">Altman et al., 2016</xref>; <xref ref-type="bibr" rid="bib35">Hensley et al., 2013</xref>; <xref ref-type="bibr" rid="bib33">Gorrini et al., 2013</xref>; <xref ref-type="bibr" rid="bib58">Mak et al., 2017</xref>). The de novo synthesis of GSH requires glycine, cysteine and glutamate as metabolic precursors. We envisioned that glutamine-derived glutamate partially fulfils the requirement of de novo synthesis of GSH in T<sub>H</sub>17 cells (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). To test this hypothesis, we followed U-<sup>13</sup>C,<sup>15</sup>N labeled glutamine incorporation into glutamate and GSH. The <sup>13</sup>C<sub>5</sub> isotopologues (generated via a direct Glutamine to Glutmate conversion) represented a significant fraction of the total glutamate and GSH pool in both T<sub>H</sub>17 and iT<sub>reg</sub> cells, however, the absolute quantity of <sup>13</sup>C<sub>5</sub>-glutamate and <sup>13</sup>C<sub>5</sub>-GSH is higher in T<sub>H</sub>17 cells than in iT<sub>reg</sub> cells (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). These results suggested that T<sub>H</sub>17 cells could uptake more glutamine and/or produce more glutamate for GSH synthesis than iT<sub>reg</sub> cells. In accord with this data, glutamine starvation reduced GSH content in a time-dependent manner in T<sub>H</sub>17 cells (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>). In addition to support GSH biosynthesis, glutamine-derived glutamate can also feed into the TCA cycle. We therefore utilized radiochemical-based approaches to assess activities of glutamine oxidation through the TCA cycle in T<sub>H</sub>17 and iT<sub>reg</sub> cells. T<sub>H</sub>17 cells displayed higher glutamine oxidation activity, indicated by <sup>14</sup>CO<sub>2</sub> release from [U-<sup>14</sup>C]-glutamine, than did iT<sub>reg</sub> cells (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). However, mitochondria-dependent pyruvate oxidation through the TCA cycle, indicated by <sup>14</sup>CO<sub>2</sub> release from [2-<sup>14</sup>C]-pyruvate, was comparable between the two functional subsets (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). These data further suggested that the overall uptake and consumption of glutamine, including oxidation of glutamate through the TCA cycle and utilization of glutamate for GSH biosynthesis is enhanced in T<sub>H</sub>17 comparing to iT<sub>reg</sub> cells. Also, qPCR analyses revealed marked upregulation of genes encoding various molecules involved in glutamine catabolism and GSH metabolism in T<sub>H</sub>17 compared to iT<sub>reg</sub> cells (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B and C</xref>). Consistent with this, deprivation of glutamine significantly suppressed T<sub>H</sub>17 but moderately enhanced iT<sub>reg</sub> cell differentiation (<xref ref-type="fig" rid="fig6">Figure 6D</xref>), while both T<sub>H</sub>17 and iT<sub>reg</sub> differentiation required glucose (<xref ref-type="fig" rid="fig6">Figure 6E</xref>). Next, we asked if pharmacological inhibition of the rate-limiting glutaminolyic enzyme glutaminase (Gls) could impact T cell differentiation. Two Gls1 specific inhibitors, bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl) ethyl sulfide (BPTES) and CB-839 (<xref ref-type="bibr" rid="bib106">Wang et al., 2010</xref>; <xref ref-type="bibr" rid="bib50">Le et al., 2012</xref>), slightly enhanced IL-17 expression (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1D</xref>). However, 6-diazo-5-oxo-l-norleucine (DON), an analog of glutamine with broad inhibitory effects glutamine utilizing enzymes (<xref ref-type="bibr" rid="bib83">Pinkus, 1977</xref>; <xref ref-type="bibr" rid="bib94">Shapiro et al., 1979</xref>), skewed away T cells from T<sub>H</sub>17 toward iT<sub>reg</sub> differentiation (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1D</xref>). In addition, DON but not BPTES and CB-839 significantly enhanced ROS production under T<sub>H</sub>17-polarizing condition (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1E</xref>). These results suggested that other glutamine utilizing enzymes including glutamine-dependent amidotransferase and Gls2, the latter of which has been shown to be induced upon T cell activation (<xref ref-type="bibr" rid="bib107">Wang et al., 2011</xref>; <xref ref-type="bibr" rid="bib116">Zalkin and Smith, 1998</xref>; <xref ref-type="bibr" rid="bib60">Massière and Badet-Denisot, 1998</xref>).Glutamine catabolism is not only coupled to the de novo synthesis of GSH, but also generates the anaplerotic substrate, α-ketoglutarate (α-KG), and substrates for nucleotide biosynthesis(<xref ref-type="bibr" rid="bib3">Altman et al., 2016</xref>). A previous study demonstrated that glutamine deprivation enhances iTreg differentiation and addition of α-KG could compromise such effect (<xref ref-type="bibr" rid="bib47">Klysz et al., 2015</xref>). In line with this report, addition of either hypoxanthine and thymidine (HT) or α-KG was able to partially rescue T<sub>H</sub>17 differentiation in glutamine-free condition without impacting ROS level (<xref ref-type="fig" rid="fig6">Figure 6F and G</xref>). While NAC treatment is sufficient to suppress ROS production, it was incapable of rescuing T<sub>H</sub>17 differentiation (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1G</xref>). However, the combination of HT and NAC led to more differentiated T<sub>H</sub>17 cells and lower level of ROS comparing to HT treatment alone in the absence of glutamine (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1F</xref>). Taken together, our studies suggest that glutamine catabolism directs the lineage choices between T<sub>H</sub>17 and iT<sub>reg</sub> cells through supporting T cell proliferation by providing biosynthetic precursors. In addition, glutamine-derived glutamate provides a key substrate for the de novo synthesis of GSH, modulates ROS signaling, and may also impact T cell differentiation (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>).</p><fig-group><fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.36158.020</object-id><label>Figure 6.</label><caption><title>Glutamate that fuels GSH de novo synthesis is partially derived from glutamine in T cells.</title><p>(<bold>A</bold>) Diagram of metabolic steps linked to the GSH production, with metabolic pathways highlighted in red. (<bold>B</bold>) Naive CD4<sup>+</sup> T cells from C57BL/6 mice were differentiated under T<sub>H</sub>17 and iT<sub>reg</sub>–inducing conditions for 5 days, followed by culturing in media containing <sup>13</sup>C<sub>5</sub><sup>15</sup>N<sub>2</sub>-glutamine. The intracellular levels of Glutamate and GSH including <sup>13</sup>C-, <sup>13</sup>C,<sup>15</sup>N-, and <sup>12</sup>C-unlabeled forms were determined by IC-UHRFTMS. (<bold>C</bold>) Naive CD4<sup>+</sup> T cells from C57BL/6 mice were differentiated under T<sub>H</sub>17 or iT<sub>reg</sub> cell–inducing conditions for 5 days, were used for measuring the generation of <sup>14</sup>CO2 from [U-<sup>14</sup>C]-glutamine (glutaminolysis), from [2-<sup>14</sup>C]-pyrvuate (TCA). (<bold>D–E</bold>) Naive CD4<sup>+</sup> T cells from C57BL/6 mice were differentiated in completed, glutamine-free (Q free) or glucose-free (G free) medium under T<sub>H</sub>17 or iT<sub>reg</sub> cell-inducing conditions for 5 days, followed by intracellular staining of IL-17 and Foxp3. (<bold>F</bold>) Naive CD4<sup>+</sup> T cells from C57BL/6 mice were activated in complete medium for 24 hr and cells were washed with PBS and switch to conditional medium in presence or absence of glutamine, 3 mM αKG or 100 μM hypoxanthine and 16 μM thymidine (HT) for 5 days followed by intracellular staining of IL-17 and (<bold>G</bold>) and ROS. Data represent the mean ±S.D.</p><p><supplementary-material id="fig6sdata1"><object-id pub-id-type="doi">10.7554/eLife.36158.024</object-id><label>Figure 6—source data 1.</label><caption><title>Source data for B, C and G.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-36158-fig6-data1-v2.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-36158-fig6-v2"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.36158.021</object-id><label>Figure 6—figure supplement 1.</label><caption><title>Glutamine catabolism is required for driving T<sub>H</sub>17 and iT<sub>reg</sub> cell differentiation.</title><p>(<bold>A</bold>) Naive CD4 +T cells from C57BL/6 mice were differentiated with T<sub>H</sub>17 cell -inducing conditions for 5 days in complete medium and cells were washed and cultured in Q-free medium as indicated time followed by the measurement of GSH. (<bold>B–C</bold>) RNAs were isolated from cells differentiated under T<sub>H</sub>17 or iT<sub>reg</sub>-inducing conditions for 3–5 days, and used for real-time qPCR analyses of indicated metabolic genes. Expression levels in T<sub>H</sub>17 group were set to 1. (<bold>D</bold>) Naive CD4<sup>+</sup> T cells from C57BL/6 mice were differentiated in presence of 30 µM DON, 25 µM BPTES and 25 µM CB-839 under T<sub>H</sub>17 cell -inducing conditions for 5 days, followed by intracellular staining of IL-17 and Foxp3 (<bold>E</bold>) ROS production by measuring the DCF-fluorescence intensity and the data was represented by histogram (upper panel) and relative intensity by bar graph (lower panel). (<bold>F</bold>) Naive CD4<sup>+</sup> T cells from C57BL/6 mice were differentiated in presence and absence of glutamine and 5 mM NAC, 100 μM hypoxanthine and 16 μM thymidine (HT) and in combination of HT and NAC under T<sub>H</sub>17 cell-inducing conditions for 5 days, followed by intracellular staining of IL-17 (<bold>G</bold>). Bar graph shows the relative value of mean fluorescence intensity of ROS measurement. Data represent the mean ±S.D of two-three independent experiments.</p><p><supplementary-material id="fig6s1sdata1"><object-id pub-id-type="doi">10.7554/eLife.36158.022</object-id><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>Source data for A, B, C, E and G.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-36158-fig6-figsupp1-data1-v2.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-36158-fig6-figsupp1-v2"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.36158.023</object-id><label>Figure 6—figure supplement 2.</label><caption><title>Glutamine catabolism coordinates with GSH metabolism in modulating ROS homeostasis and T cell differentiation.</title><p>Modulation of GSH biosynthesis and ROS production in directing T cell differentiation.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-36158-fig6-figsupp2-v2"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>A robust T cell-mediated adaptive immune response results from the clonal expansion of antigen-specific T cells and subsequent differentiation into diverse functional subsets to fine-tune responses against challenge. Both the cellular proliferation during expansion and the cytokine production associated with differentiation exert high bioenergetic and biosynthetic demand on T cells. Accordingly, rapidly evolving pathogens often impose selective pressures on the regulation of central metabolic pathways that fuel cell proliferation and differentiation, allowing T cells to maintain homeostasis while remaining ready to mount rapid responses under diverse metabolic and immune conditions. The inability to accommodate the metabolic and bioenergetic demands of T cell proliferation and differentiation can impair the proper development and function of T cells. Beyond this, the availability of specific metabolites, and the pathways that process them, interconnect with signaling events in the cell to orchestrate metabolic checkpoints which influence T cell activation, differentiation, and immune function (<xref ref-type="bibr" rid="bib108">Wang and Green, 2012</xref>; <xref ref-type="bibr" rid="bib6">Bensinger and Tontonoz, 2008</xref>; <xref ref-type="bibr" rid="bib31">Gerriets and Rathmell, 2012</xref>; <xref ref-type="bibr" rid="bib80">Pearce et al., 2013</xref>; <xref ref-type="bibr" rid="bib13">Chi, 2012</xref>; <xref ref-type="bibr" rid="bib84">Powell and Delgoffe, 2010</xref>; <xref ref-type="bibr" rid="bib64">Michalek and Rathmell, 2010</xref>; <xref ref-type="bibr" rid="bib36">Ho et al., 2015</xref>). Here, we found that glucose plays an indispensable role in driving T<sub>H</sub>17 and iT<sub>reg</sub> cell differentiation, while glutamine is only required for T<sub>H</sub>17 cell differentiation. Glutamine catabolism is coupled with de novo GSH synthesis and is preferentially elevated during T<sub>H</sub>17 but not iT<sub>reg</sub> cell differentiation, suggesting that different T cell lineages ‘wire’ metabolism differently to support their development and function. Previous studies have suggested that engagement of the transcription factor hypoxia-inducible factor 1α (HIF1α) coordinates glycolysis and T cell signaling cascades to regulate the differentiation of T<sub>H</sub>17 and iTreg cells (<xref ref-type="bibr" rid="bib95">Shi et al., 2011</xref>; <xref ref-type="bibr" rid="bib18">Dang et al., 2011</xref>). While the high rate of glutamine catabolism ensures the capacity to supply glutamate, glycolysis provides ATP and biosynthetic precursors for glycine, fulfilling the needs of de novo synthesis of GSH during T cell differentiation. Our results using genetic modulation of metabolic enzymes suggest that de novo synthesis of GSH but not recycling from GSSG is required for fine-tuning ROS and directing the differentiation of T<sub>H</sub>17 and T<sub>reg</sub> cells. We further found that dimethyl fumarate, a FDA approved drug (BG-12/Tecfidera) for multiple sclerosis, suppresses T<sub>H</sub>17 differentiation by augmenting intracellular ROS. While previous studies clearly demonstrate that activation-induced metabolic reprogramming is required for driving T cell growth and proliferation, our studies shed light on the complex utilization of the glutamine catabolic pathway and implicate ROS as essential metabolic signals that dictate T cell lineage engagement.</p><p>Prokaryotic and eukaryotic cells have evolved to maintain reducing intracellular conditions by generating reducing equivalents, NADPH and GSH, enabling cells to fine-tune the ROS levels that are required for fulfilling vital cellular functions. Accordingly, oxidative stress occurs if the balance between ROS production and antioxidant capacity is disturbed, thereby leading to the accumulation of oxidized biomolecules. T cell receptor (TCR) engagement induces a rapid generation of mitochondrial ROS from OXPHOS and cytoplasmic ROS from NADPH oxidases (NOXs), a family of plasma membrane associated oxidases (<xref ref-type="bibr" rid="bib93">Sena et al., 2013</xref>; <xref ref-type="bibr" rid="bib42">Kamiński et al., 2012</xref>; <xref ref-type="bibr" rid="bib38">Jackson et al., 2004</xref>). T cells with reduced production of mitochondrial ROS display impaired production of interleukin 2 (IL-2) and antigen-specific proliferation, indicating an essential signaling role for mitochondrial ROS in driving optimal TCR signaling (<xref ref-type="bibr" rid="bib93">Sena et al., 2013</xref>; <xref ref-type="bibr" rid="bib42">Kamiński et al., 2012</xref>). Beyond that, NOX-dependent ROS also plays a role in modulating TCR signaling and T cell differentiation. T cells with low levels of ROS due to NOX deficiency are skewed toward a T<sub>H</sub>17 phenotype (<xref ref-type="bibr" rid="bib38">Jackson et al., 2004</xref>; <xref ref-type="bibr" rid="bib86">Purushothaman and Sarin, 2009</xref>; <xref ref-type="bibr" rid="bib75">Padgett and Tse, 2016</xref>; <xref ref-type="bibr" rid="bib104">Tse et al., 2010</xref>). Our studies suggest that de novo synthesis of GSH is essential for fine-tuning ROS levels in T cells and also indicate the differential requirements for the level of ROS in driving T cell lineage engagement toward T<sub>H</sub>17 or iT<sub>reg</sub> cells. Understanding the metabolic process of GSH synthesis and ROS generation during T cell differentiation may also impact the development of safer and more effective therapies for autoimmune and inflammation diseases. Dimethyl fumarate (DMF) is a cellular permeable analog of fumarate and the key active ingredient of BG-12/TECFIDERA and FUMADERM, a first-line oral treatment for relapsing multiple sclerosis (<xref ref-type="bibr" rid="bib14">CONFIRM Study Investigators et al., 2012</xref>; <xref ref-type="bibr" rid="bib2">ALLEGRO Study Group et al., 2012</xref>). However, the cellular and molecular mechanisms of DMF therapy remain largely elusive. DMF has been suggested to impact a plethora of cellular and molecular targets, including Nrf2 and GPCRs in T cells, dendritic cells (DCs), endothelial cells, and neurons (<xref ref-type="bibr" rid="bib7">Blewett et al., 2016</xref>; <xref ref-type="bibr" rid="bib92">Schulze-Topphoff et al., 2016</xref>; <xref ref-type="bibr" rid="bib110">Wang et al., 2015</xref>; <xref ref-type="bibr" rid="bib12">Chen et al., 2014</xref>; <xref ref-type="bibr" rid="bib81">Peng et al., 2012</xref>; <xref ref-type="bibr" rid="bib52">Linker and Gold, 2013</xref>; <xref ref-type="bibr" rid="bib22">Duffy et al., 1998</xref>; <xref ref-type="bibr" rid="bib32">Gill and Kolson, 2013</xref>). Consistent with the studies showing that DMF can neutralize GSH in vitro (<xref ref-type="bibr" rid="bib118">Zheng et al., 2015</xref>; <xref ref-type="bibr" rid="bib101">Sullivan et al., 2013</xref>), our data indicate that the ability of DMF to augment ROS and suppress T<sub>H</sub>17 cell differentiation contributes to its therapeutic effect.</p><p>We found that DMF treatment induced a compensatory NRF2-mediated anti-oxidative response and NRF2 deficiency exacerbated the ROS-producing effects of DMF in T<sub>H</sub>17 cells. Also, NRF2 and its target genes were highly upregulated in T<sub>H</sub>17 cells, suggesting that T<sub>H</sub>17 cells preferentially maintain a low degree of oxidative stress partially by engaging the NRF2 signaling pathway. In addition to GSH production and consumption, NRF2 controls thioredoxin (TXN) production and consumption through transcriptional regulation of its target genes including thioredoxin reductase 1 (TXNRD1). Both GSH and TXN are important anti-oxidation systems and appear functionally redundant in most organisms (<xref ref-type="bibr" rid="bib17">Couto et al., 2016</xref>; <xref ref-type="bibr" rid="bib72">Mustacich and Powis, 2000</xref>; <xref ref-type="bibr" rid="bib51">Lei et al., 2016</xref>; <xref ref-type="bibr" rid="bib55">Lu and Holmgren, 2014</xref>). However, recent studies implicate the presence of a dynamic cross-talk between these two systems. Glutaredoxin (GRX)-GSH can reduce oxidized TXN in the absence of thioredoxin reductase. Conversely, TXN-TXNRD can also function as an alternative system to reduce GSSG to GSH (<xref ref-type="bibr" rid="bib21">Du et al., 2012</xref>; <xref ref-type="bibr" rid="bib103">Tan et al., 2010</xref>; <xref ref-type="bibr" rid="bib41">Johansson et al., 2004</xref>; <xref ref-type="bibr" rid="bib34">Hanschmann et al., 2010</xref>). Collectively, these data indicate that the TXN and GSH systems can backup for each other under certain conditions. Consistent with the overlapping function of the GSH and TXN system, the inhibition of TXNRD rendered cancer cells susceptible to the depletion of GSH (<xref ref-type="bibr" rid="bib59">Mandal et al., 2010</xref>; <xref ref-type="bibr" rid="bib53">Lu et al., 2007</xref>; <xref ref-type="bibr" rid="bib109">Wang et al., 2012</xref>). Although our data suggest that the de novo synthesis of GSH is sufficient to maintain ROS homeostasis in the absence of Gsr dependent GSSG-GSH recycling, it is still conceivable that thioredoxin reductase may partially compensate for the loss of Gsr by backing up the recycle of GSSG to GSH in T cells. It has been shown that TXN can be secreted by CD4<sup>+</sup> T cells and may modulate the expression of T cell surface receptor and proliferation (<xref ref-type="bibr" rid="bib89">Rosen et al., 1995</xref>; <xref ref-type="bibr" rid="bib105">Wakasugi et al., 1990</xref>; <xref ref-type="bibr" rid="bib61">Matthias et al., 2002</xref>; <xref ref-type="bibr" rid="bib102">Tagaya et al., 1990</xref>). As such, we envision that the combination of DMF and pharmacological approaches that target TXN system may represent a more effective strategy than DMF alone for treating T cell-mediated inflammation and autoimmune disease.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type <break/>(species) or <break/>resource</th><th>Designation</th><th>Source or reference</th><th>Identifiers</th><th>Additional <break/>information</th></tr></thead><tbody><tr><td>Strain, strain <break/>background <break/>(Mus musculus)</td><td>C57BL/6 (B6) mice</td><td/><td>Taconic</td><td/></tr><tr><td>Strain, strain <break/>background <break/>(Mus musculus)</td><td valign="bottom">C3H/HeN</td><td/><td>Envigo</td><td/></tr><tr><td>Genetic <break/>reagent <break/>(Mus musculus)</td><td valign="bottom"><italic>CD4-Cre</italic> <break/><italic>Gclc<sup>flox/flox</sup></italic></td><td>PMID:23226398</td><td/><td valign="bottom"/></tr><tr><td>Genetic <break/>reagent <break/>(Mus musculus)</td><td valign="bottom"><italic>Gclm-</italic>KO</td><td>PMID:12384496</td><td/><td/></tr><tr><td>Genetic <break/>reagent <break/>(Mus musculus)</td><td valign="bottom"><italic>ROSA26CreERT2</italic></td><td>RRID: <break/><ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/IMSR_JAX:008463">IMSR_JAX:008463</ext-link></td><td>The Jackson <break/>Laboratory</td><td/></tr><tr><td>Genetic <break/>reagent <break/>(Mus musculus)</td><td valign="bottom"><italic>GSR-</italic>KO</td><td>PMID: 10218442</td><td/><td/></tr><tr><td>Antibody</td><td>Mouse anti- <break/>CD3 mAb</td><td>Cat. #:BE0001-1, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_1107634">AB_1107634</ext-link></td><td>BioXcell</td><td/></tr><tr><td>Antibody</td><td>Mouse anti- <break/>CD28 mAb</td><td>Cat. #BE0015-1 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_1107624">AB_1107624</ext-link></td><td>BioXcell</td><td/></tr><tr><td>Antibody</td><td>Mouse anti <break/>-IL2 mAb</td><td>Cat.#BE0043 <break/>RRID::AB_1107702</td><td>BioXcell</td><td/></tr><tr><td>Antibody</td><td>Mouse anti- <break/>IL4 mAb</td><td>Cat. #BE0045 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_1107707">AB_1107707</ext-link></td><td>BioXcell</td><td/></tr><tr><td>Antibody</td><td>Mouse anti- <break/>IFNγ mAb</td><td>Cat. #BE0055 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_1107694">AB_1107694</ext-link></td><td>BioXcell</td><td/></tr><tr><td>Antibody</td><td>Anti mouse <break/>CD4-FITC</td><td>Cat. #11–0042 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_464897">AB_464897</ext-link></td><td>eBioscience</td><td>(1:200)</td></tr><tr><td>Antibody</td><td>Anti mouse <break/>CD4-APC</td><td>Cat. #17-0041-81 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_469319">AB_469319</ext-link></td><td>eBioscience</td><td>(1:200)</td></tr><tr><td>Antibody</td><td>Anti mouse <break/>CD8-APC-Cy7</td><td>Cat. #100714 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_312753">AB_312753</ext-link></td><td>Biolegend</td><td>(1:200)</td></tr><tr><td>Antibody</td><td>Anti mouse <break/>Foxp3-APC</td><td>Cat. # <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_469456">AB_469456</ext-link></td><td>eBioscience</td><td>(1:200)</td></tr><tr><td>Antibody</td><td>Anti mouse <break/>IL-17A-PECy7</td><td>Cat. #25-7177-82 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10732356">AB_10732356</ext-link></td><td>eBioscience</td><td>(1:200)</td></tr><tr><td>Antibody</td><td>Anti GCLC antibody <break/>(rabbit monoclonal)</td><td>Cat. #ab190685 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10975474">AB_10975474</ext-link></td><td>Abcam</td><td>WB (1:1000)</td></tr><tr><td>Antibody</td><td>Anti GCLM antibody <break/>(rabbit monoclonal)</td><td>Cat. #ab124827 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10975474">AB_10975474</ext-link></td><td>Abcam</td><td>WB (1:1000)</td></tr><tr><td>Antibody</td><td>anti-mouse <break/>CD25 -PE</td><td>Cat. #101904 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_312847">AB_312847</ext-link></td><td>Biolegend</td><td>(1:200)</td></tr><tr><td>Antibody</td><td>anti-mouse <break/>CD69-PECy7</td><td>Cat. #552879 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_394508">AB_394508</ext-link></td><td>BD Bioscience</td><td>(1:200)</td></tr><tr><td>Antibody</td><td>Anti mouse <break/>monoclonal CD3</td><td>Cat. #sc-101442 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_1120355">AB_1120355</ext-link></td><td>Santa Cruz</td><td>IHC (1:50)</td></tr><tr><td>Antibody</td><td>Anti mouse <break/>monoclonal <break/>galectin-3</td><td>Cat. #sc-32790, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_627657">AB_627657</ext-link></td><td>Santa Cruz</td><td>IHC (1:50)</td></tr><tr><td>Peptide, <break/>recombinant protein</td><td>MOG35-55 peptide</td><td>synthesized <break/>and HPLC-purified</td><td>St. Jude <break/>Hartwell Center <break/>for Biotechnology</td><td/></tr><tr><td>Peptide, <break/>recombinant protein</td><td>Recombinant <break/>mouse IL-6</td><td>216–16</td><td>Peprotech</td><td/></tr><tr><td>Peptide, <break/>recombinant protein</td><td>Recombinant <break/>human TGFb</td><td>100–21 c</td><td>Peprotech</td><td/></tr><tr><td>Peptide, <break/>recombinant protein</td><td>Recombinant <break/>human or mouse IL-2</td><td>200–02</td><td>Peprotech</td><td/></tr><tr><td>Commercial <break/>assay or kit</td><td>Foxp3/Transcription <break/>Factor Staining <break/>Buffer Set</td><td>00-5523-00</td><td>e-Bioscience</td><td/></tr><tr><td>Commercial <break/>assay or kit</td><td>Naive CD4 + T cell <break/>isolation kit,mouse</td><td>5160725186</td><td>Miltenyi Biotec</td><td/></tr><tr><td>Commercial <break/>assay or kit</td><td>CD45R(B220) <break/>microbeads, mouse</td><td>5150309030</td><td>Miltenyi Biotec</td><td/></tr><tr><td>Commercial <break/>assay or kit</td><td>ABC kit</td><td>PK-7200</td><td>Vector <break/>laboratories</td><td/></tr><tr><td>Commercial <break/>assay or kit</td><td>MojoSort Mouse <break/>naive CD4 T Cell <break/>Isolation Kit</td><td>480031</td><td>Biolegend</td><td/></tr><tr><td>Chemical <break/>compound, drug</td><td>Diethly Fumerate</td><td>Sigma Aldrich</td><td>D95654</td><td/></tr><tr><td>Chemical <break/>compound, drug</td><td>N-Acetyl-L-cysteine</td><td>Sigma-Aldrich</td><td>A7250</td><td/></tr><tr><td>Chemical <break/>compound, drug</td><td>Tamofixen</td><td>Sigma-Aldrich</td><td>T5648</td><td/></tr><tr><td>Chemical <break/>compound, drug</td><td>4-hydroxytamoxifen</td><td>Sigma</td><td>H7904</td><td/></tr><tr><td>Chemical <break/>compound, drug</td><td>Dimethy a-keto <break/>glutarate/aKG</td><td>Sigma-Aldrich</td><td>34963–1</td><td/></tr><tr><td>Chemical <break/>compound, drug</td><td>Hypoxathine</td><td>Sigma-Aldrich</td><td>H9377</td><td/></tr><tr><td>Chemical <break/>compound, drug</td><td>Thymidine</td><td>Sigma</td><td>T9250</td><td/></tr><tr><td>Chemical <break/>compound, drug</td><td>H2O2</td><td>Sigma-Aldrich</td><td>7722-84-1</td><td/></tr><tr><td>Chemical <break/>compound, drug</td><td>carboxyfluorescein <break/>diacetate <break/>succinimidyl <break/>ester(CFSE)</td><td>Invitrogen</td><td>C1157</td><td/></tr><tr><td>Chemical <break/>compound, drug</td><td>DM-H2DCFDA</td><td>Invitrogen</td><td>C6827</td><td/></tr><tr><td>Chemical <break/>compound, drug</td><td>DAB</td><td>Vector <break/>Laboratories</td><td>SK-4100</td><td/></tr><tr><td>Chemical <break/>compound, drug</td><td>Monobromobimane</td><td>Invitrogen</td><td>M1378</td><td/></tr><tr><td>Chemical <break/>compound, drug</td><td>7-amino- <break/>actinomycin D(7AAD)</td><td>Biolegend</td><td>420404</td><td/></tr><tr><td>Chemical <break/>compound, drug</td><td>Pertussis toxin</td><td>181</td><td>List Biological <break/>Laboratories</td><td/></tr><tr><td>Chemical <break/>compound, drug</td><td>Mycobacterium <break/>tuberculosum</td><td>231141</td><td>Difco</td><td/></tr><tr><td>Chemical <break/>compound, drug</td><td>Incomplete <break/>Freund’s Adjuvant</td><td>263910</td><td>Difco</td><td/></tr><tr><td>Chemical <break/>compound, drug</td><td>[U-14C]-glutamine</td><td>MC 1124</td><td>Moravek</td><td/></tr><tr><td>Chemical <break/>compound, drug</td><td>[2–14C]-pyruvate</td><td>ARC 0222</td><td>American <break/>Radiolabeled <break/>Chemicals</td><td/></tr><tr><td>Chemical <break/>compound, drug</td><td valign="bottom">Cell Stimulation <break/>Cocktail (plus <break/>protein transport <break/>inhibitors) (500X)</td><td>00-4975-93</td><td>eBioscience</td><td/></tr><tr><td>Chemical <break/>compound, drug</td><td>Iscove's Modified <break/>Dulbecco's Media <break/>- Glucose free <break/>conditional medium</td><td>ME17058P1</td><td>Thermo <break/>Fisher Scientific</td><td/></tr><tr><td>Chemical <break/>compound, drug</td><td>Iscove's Modified <break/>Dulbecco's Media <break/>- without L-glutamine</td><td>12–726 f</td><td>Lonza</td><td/></tr><tr><td>Chemical <break/>compound, drug</td><td>RPMI 1640 <break/>Medium, No Glucose</td><td>11-879-020</td><td>Gibco</td><td/></tr><tr><td>Chemical <break/>compound, drug</td><td>Hyclone RPMI <break/>1640 Medium, <break/>no glutamine</td><td>sh30096.10</td><td>Thermo <break/>Fisher Scientific</td><td/></tr><tr><td>Chemical <break/>compound, drug</td><td>U-13C6-glutamine</td><td>CNLM-1275–0.1</td><td>Cambridge <break/>Isotope Lab</td><td/></tr><tr><td>Chemical <break/>compound, drug</td><td>6-Diazo-5-oxo-L <break/>-norleucine</td><td valign="bottom">D2141-5MG</td><td>Sigma-aldrich</td><td/></tr><tr><td>Chemical <break/>compound, drug</td><td>Bis-2- <break/>(5-phenylacetamido <break/>-1,3,4-thiadiazol-2-yl) <break/>ethyl sulfide (BPTES)</td><td valign="bottom">SML0601</td><td>Sigma-aldrich</td><td/></tr><tr><td>Chemical <break/>compound, drug</td><td>CB-839</td><td>22038</td><td>Cayman</td><td/></tr><tr><td>Software, <break/>algorithm</td><td>Graphpad Prism</td><td/><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002798">SCR_002798</ext-link></td><td/></tr><tr><td>Software, <break/>algorithm</td><td>FlowJo</td><td/><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_008520">SCR_008520</ext-link></td><td/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Mice</title><p> <italic>Gsr-</italic>KO mice are on C3H/HeN background and <italic>ROSA26CreERT2, CD4-Cre, Gclm-</italic>KO, and <italic>Gclc<sup>flox/flox</sup></italic> are on the C57BL/6 background and were previously described (<xref ref-type="bibr" rid="bib107">Wang et al., 2011</xref>; <xref ref-type="bibr" rid="bib11">Chen et al., 2007</xref>; <xref ref-type="bibr" rid="bib114">Yang et al., 2002</xref>; <xref ref-type="bibr" rid="bib88">Rogers et al., 2004</xref>; <xref ref-type="bibr" rid="bib85">Pretsch, 1999</xref>; <xref ref-type="bibr" rid="bib113">Yan et al., 2012</xref>) C57BL/6 mice were purchased from Envigo (formly Harlan). Mice at 8–12 weeks of age were used in the experiment and were kept in specific pathogen-free conditions within the Animal Resource Center at the Research Institute at Nationwide Children’s Hospital or St. Jude Children's, Research Hospital. Animal protocols were approved by the Institutional Animal Care and Use Committee of the Research Institute at Nationwide Children’s Hospital or St. Jude Children's Research Hospital.</p></sec><sec id="s4-2"><title>Flow cytometry</title><p>For analysis of surface markers, cells were stained in PBS containing 2% (wt/vol) BSA and the appropriate antibodies from eBioscience. Foxp3 staining was performed according to the manufacturer's instructions (eBioscience). For IL-17A intracellular cytokine staining, T cells were stimulated for 4-5 h with phorbol 12-myristate 13-acetate (PMA) and ionomycin in the presence of monensin before being stained according to the manufacturer's instructions (BD Bioscience). For ROS measurement, cells were cultured in fresh serum-free IMDM media containing 5 μM H<sub>2</sub>DCF-DA (BD Bioscience) for 30 min at 37°C before being washed and resuspended with serum-free IMDM media. The fluorescence intensity was measured by flow cytometry. For GSH measurement, cells were cultured in PBS (1%FBS) containing 50μM monobromobimane (Biochemika) for 10 min at 37°C before being washed and resuspended with PBS. The fluorescence at 450/50 nm (blue spectra) was measured by flow cytometry (<xref ref-type="bibr" rid="bib15">Cossarizza et al., 2009</xref>). Flow cytometry data were acquired on Novocyte (ACEA Biosciences) or LSRII (Becton Dickinson) and were analyzed with FlowJo software (TreeStar).</p></sec><sec id="s4-3"><title>Cell purification and culture</title><p>Total T cells or naive CD4<sup>+</sup> T cells were enriched from spleens and lymph nodes by negative selection using MACS systems (Miltenyi Biotec, Auburn, CA) following the manufacturer’s instructions. Freshly isolated total T cells with 75-80% CD3 positivity were either maintained in culture media with 5ng/ml IL7 or were stimulated with IL-2 (100U/ml) and plate-bound anti-CD3 (clone 145-2C11) and anti-CD28 (clone 37.51). Plates were pre-coated with 2 μg/ml antibodies overnight at 4°C. Cells were cultured in RPMI 1640 media supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 0.05 mM <italic>2-mercaptoethanol</italic>, 100 units/ml penicillin and 100 μg/ml streptomycin at 37 °C in 5% CO2. For CFSE dilution analysis, cells were pre-incubated for 10 min in 4 μM CFSE (Invitrogen) in PBS plus 5% FBS before culture. For iT<sub>reg</sub> cell differentiation, 0.5 x10<sup>6</sup> naive CD4<sup>+</sup> T cells were stained with 4 μM CFSE and cultured with 100 U/ml IL-2, 5ng/ml TGF-β and 20ng/ml IL-6 in 0.5ml RPMI-1640 media (containing 10% (v/v) heat-inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 0.05 mM <italic>2-mercaptoethanol</italic>, 100 units/ml penicillin and 100 μg/ml streptomycin) in 48-well tissue culture plate that was pre-coated with 10µg/ml anti-CD3 and 10µg/ml anti-CD28 overnight at 4°C . For T<sub>H</sub>17 conditions, 0.5 x10<sup>6</sup> naive CD4<sup>+</sup> T cells and 5 x10<sup>6</sup> irradiated splenocytes (artificial APC) were cultured with 2 μg/ml anti-CD3 (2C11; Bio X Cell), 2 μg/ml anti-CD28 (37.51; Bio X Cell), 8 μg/ml anti–IL-2, 8 μg/ml anti–IL-4, 8 μg/ml anti–IFN-γ, 2 ng/ml TGF-β, and 20-50ng/ml IL-6 in 1ml IMDM media (containing 15% (v/v) heat-inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 0.05 mM <italic>2-mercaptoethanol</italic>, 100 units/ml penicillin and 100 μg/ml streptomycin) in 24-well tissue culture plate). For metabolic starvation experiment, Glucose or Glutamine-free IMDM and RPMI-1640 medium was supplemented with 10% (v/v) heat-inactivated dialyzed fetal bovine serum (DFBS). For T<sub>H</sub>17 rescue experiments, 0.5 x10<sup>6</sup> naive CD4+ T cells were activated in complete IMDM medium. After 24 h cells were switched to conditional glutamine-free IMDM medium for 4 days. DFBS was made dialyzing against 100 volumes of distilled water (six changes in three days) using Slide-ALyzer G2 dialysis cassettes with cut-through MW size 2K (ThermoFisher Scientific) at 4⁰C.</p></sec><sec id="s4-4"><title>qPCR and immunoblot analysis.</title><p>Total RNA was isolated using the RNeasy Mini Kit (Qiagen) and was reverse transcribed using random hexamer and M-MLV Reverse Transcriptase (Invitrogen). SYBR green-based quantitative RT-PCR was performed using the Applied Biosystems 7900 Real Time PCR System. The relative gene expression was determined by the comparative <italic>C</italic><sub>T</sub> method also referred to as the 2<sup>−ΔΔ<italic>C</italic></sup><sub>T</sub> method. The data were presented as the fold change in gene expression normalized to an internal reference gene (beta2-microglobulin) and relative to the control (the first sample in the group). Fold change=2<sup>−ΔΔ<italic>C</italic></sup><sub>T</sub>=[(<italic>C</italic><sub>Tgene of interst</sub>- <italic>C</italic><sub>Tinternal reference</sub>)]sample A-=[(<italic>C</italic><sub>Tgene of interst</sub>- <italic>C</italic><sub>Tinternal reference</sub>)]sample B. Samples for each experimental condition were run in triplicated PCR reactions. Primer sequences were obtained from Primer Bank (<xref ref-type="bibr" rid="bib97">Spandidos et al., 2010</xref>). Primer sequences are listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. Cell extracts were prepared and immunoblotted as previously described (<xref ref-type="bibr" rid="bib107">Wang et al., 2011</xref>).</p></sec><sec id="s4-5"><title>MOG immunization and EAE</title><p>Mice were immunized with 100 μg of myelin oligodendrocyte glycoprotein (MOG)<sub>35–55</sub> peptide in CFA (Difco) with 500 μg of Mycobacterium tuberculosis (Difco). Mice were i.p. injected 200 ng of pertussis toxin (List Biological,#181) on the day of immunization and 2 days later, as described (<xref ref-type="bibr" rid="bib44">Kang et al., 2010</xref>). The mice were observed daily for clinical signs and scored as described previously (<xref ref-type="bibr" rid="bib95">Shi et al., 2011</xref>).</p></sec><sec id="s4-6"><title>Histopathology and immunohistochemistry</title><p>Mice were euthanized and then were perfused with 25 ml PBS with 2 mM EDTA by heart puncture to remove blood from internal organs. Spinal cords were taken out and fixed by immersion with 10% neutral buffered formalin solution and decalcified. Spinal column was divided into cervical, thoracic and lumbar, and then was embedded in paraffin, sectioned, and stained with standard histological methods for hematoxylin and eosin (H and E). Immunohistochemistry were performed on serial histological sections according to standard protocols using anti-Mac2 and anti-CD3 (1:50, Santa Cruz). Appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies were used and detected using 3,3’-diaminobenzidine tetrahydrochloride (DAB). Slides were counterstained with hematoxylin. Microscopy images were taken using Zeiss Axio Scope A1.</p></sec><sec id="s4-7"><title>Metabolic activity analysis</title><p>Glutamine oxidation activity was determined by the rate of <sup>14</sup>CO<sub>2</sub> released from [U-<sup>14</sup>C]-glutamine (<xref ref-type="bibr" rid="bib8">Brand et al., 1984</xref>). In brief, one-five million T cells were suspended in 0.5 ml fresh media. To facilitate the collection of <sup>14</sup>CO<sub>2</sub>, cells were dispensed into 7 ml glass vials (TS-13028, Thermo) with a PCR tube containing 50 μl 0.2M KOH glued on the sidewall. After adding 0.5 μci [U-<sup>14</sup>C]-glutamine, the vials were capped using a screw cap with rubber septum (TS-12713, Thermo). The assay was stopped 2 hr later by injection of 100 μl 5N HCL and the vials were kept at room temperate overnight to trap the <sup>14</sup>CO<sub>2</sub>. The 50 μl KOH in the PCR tube was then transferred to scintillation vials containing 10 ml scintillation solution for counting. A cell-free sample containing 0.5 μci [U-<sup>14</sup>C]-glutamine was included as a background control.</p><p>Pyruvate oxidation activity was determined by the rate of <sup>14</sup>CO<sub>2</sub> released from [2-<sup>14</sup>C]-pyruvate (<xref ref-type="bibr" rid="bib112">Willems et al., 1978</xref>). In brief, one to five million T cells were suspended in 0.5 ml fresh T cell media. To facilitate the collection of <sup>14</sup>CO<sub>2</sub>, cells were dispensed into 7 ml glass vials (TS-13028, Thermo) with a PCR tube containing 50 μl 0.2M KOH glued on the sidewall. After adding 0.5 μci [2-<sup>14</sup>C]-pyruvate, the vials were capped using a screw cap with rubber septum (TS-12713, Thermo). The assay was stopped 2 hr later by injection of 100 μl 5N HCL and the vials were kept at room temperate overnight to trap the <sup>14</sup>CO<sub>2</sub>. The 50 μl KOH in PCR tube was then transferred to scintillation vials containing 10 ml scintillation solution for counting. A cell-free sample containing 0.5 μci [2-<sup>14</sup>C]-pyruvate was included as a background control.</p></sec><sec id="s4-8"><title>Metabolite extraction and analysis by ion chromatography-ultra high resolution-Fourier transform mass spectrometry (IC-UHR-FTMS)</title><p>Cells were cultured in glutamine-free media with 2 mM <sup>13</sup>C<sub>5</sub><sup>15</sup>N<sub>2</sub>-glutamine (Cambridge Isotope Laboratories) for 24 hr at 37°C and were then washed three times in cold PBS before snap freezing. The frozen cell pellets were homogenized in 60% cold CH3CN in a ball mill (Precellys- 24, Bertin Technologies) for denaturing proteins and optimizing extraction. Polar metabolites were extracted by the solvent partitioning method with a final CH3CN:H2O:CHCl3 (2:1.5:1, v/v) ratio, as described previously (<xref ref-type="bibr" rid="bib23">Fan et al., 2012</xref>). The polar extracts were lyophilized before reconstitution in nanopure water and analysis on a Dionex ICS-5000 +ion chromatography interfaced to a Thermo Fusion Orbitrap Tribrid mass spectrometer (Thermo Fisher Scientific) as previously described (<xref ref-type="bibr" rid="bib24">Fan et al., 2016</xref>) using a <italic>m/z</italic> scan range of 80–700. Peak areas were integrated and exported to Excel via the Thermo TraceFinder (version 3.3) software package before natural abundance correction (<xref ref-type="bibr" rid="bib67">Moseley, 2010</xref>). The isotopologue distributions of metabolites were calculated as the mole fractions as previously described (<xref ref-type="bibr" rid="bib49">Lane et al., 2008</xref>). The number of moles of each metabolite was determined by calibrating the natural abundance-corrected signal against that of authentic external standards. The amount was normalized to the amount of extracted protein, and is reported in µmol/g protein. Metabolome quantification of GSH and GSSG were determined by CE-MS that was carried out through a facility service at Human Metabolome Technology Inc., Tsuruoka, Japan.</p></sec><sec id="s4-9"><title>Statistical analysis</title><p> <italic>P</italic> values were calculated with Student's <italic>t</italic>-test all experiment except EAE experiments, where two way anova test was performed. <italic>P</italic> values smaller than 0.05 were considered significant, with p-values&lt;0.05, p-values&lt;0.01, and p-values&lt;0.001 indicated as *, **, and ***, respectively.</p></sec></sec></body><back><ack id="ack"> <title>Acknowledgements</title> <p>This work was supported by R21AI117547 and 1R01AI114581 from National Institute of Health, V2014-001 from the V-Foundation and 128436-RSG-15-180-01-LIB from the American Cancer Society (RW), K01AA025093 (YC), R24AA022057 (VV), the American Lebanese and Syrian Associated Charities (DG), and Natural Science Foundation of Hunan Province Grant 2018JJ2351(GL), NCI 1P01CA163223-01A1 and NIDDK 1U24DK097215-01A1 (TWMF), 130421-RSG-17-071-01-TBG from the American Cancer Society , R03 CA212802-01A1 (JY) and R21 AI113930 (YL).</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Formal analysis, Methodology, Writing—original draft</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Methodology, Writing—original draft</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con5"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con6"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con7"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con8"><p>Resources</p></fn><fn fn-type="con" id="con9"><p>Resources</p></fn><fn fn-type="con" id="con10"><p>Resources</p></fn><fn fn-type="con" id="con11"><p>Resources</p></fn><fn fn-type="con" id="con12"><p>Data curation, Methodology</p></fn><fn fn-type="con" id="con13"><p>Resources</p></fn><fn fn-type="con" id="con14"><p>Resources</p></fn><fn fn-type="con" id="con15"><p>Data curation, Methodology</p></fn><fn fn-type="con" id="con16"><p>Conceptualization, Supervision, Funding acquisition, Investigation, Methodology, Writing—original draft, Writing—review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: Animal protocols were approved by the Institutional Animal Care and Use Committee of the Research Institute at Nationwide Children's Hospital (AR13-00055)</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><object-id pub-id-type="doi">10.7554/eLife.36158.025</object-id><label>Supplementary file 1.</label><caption><title>List of primer sequences used for RT-PCR analysis.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-36158-supp1-v2.xlsx"/></supplementary-material><supplementary-material id="transrepform"><object-id pub-id-type="doi">10.7554/eLife.36158.026</object-id><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-36158-transrepform-v2.pdf"/></supplementary-material><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files.</p></sec></sec><ref-list> <title>References</title> <ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agnihotri</surname> <given-names>N</given-names></name><name><surname>Mishra</surname> <given-names>PC</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Mechanism of scavenging action of <italic>N</italic>-acetylcysteine for the OH radical: a quantum computational study</article-title><source>The Journal of Physical Chemistry B</source><volume>113</volume><fpage>12096</fpage><lpage>12104</lpage><pub-id pub-id-type="doi">10.1021/jp903604s</pub-id><pub-id pub-id-type="pmid">19768848</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>ALLEGRO Study Group</collab><name><surname>Comi</surname> <given-names>G</given-names></name><name><surname>Jeffery</surname> <given-names>D</given-names></name><name><surname>Kappos</surname> <given-names>L</given-names></name><name><surname>Montalban</surname> <given-names>X</given-names></name><name><surname>Boyko</surname> <given-names>A</given-names></name><name><surname>Rocca</surname> <given-names>MA</given-names></name><name><surname>Filippi</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Placebo-controlled trial of oral laquinimod for multiple sclerosis</article-title><source>New England Journal of Medicine</source><volume>366</volume><fpage>1000</fpage><lpage>1009</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1104318</pub-id><pub-id pub-id-type="pmid">22417253</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altman</surname> <given-names>BJ</given-names></name><name><surname>Stine</surname> <given-names>ZE</given-names></name><name><surname>Dang</surname> <given-names>CV</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>From Krebs to clinic: glutamine metabolism to Cancer therapy</article-title><source>Nature Reviews Cancer</source><volume>16</volume><fpage>619</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1038/nrc.2016.71</pub-id><pub-id pub-id-type="pmid">27492215</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ates</surname> <given-names>B</given-names></name><name><surname>Abraham</surname> <given-names>L</given-names></name><name><surname>Ercal</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Antioxidant and free radical scavenging properties of N-acetylcysteine amide (NACA) and comparison with N-acetylcysteine (NAC)</article-title><source>Free Radical Research</source><volume>42</volume><fpage>372</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1080/10715760801998638</pub-id><pub-id pub-id-type="pmid">18404536</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bennett</surname> <given-names>BD</given-names></name><name><surname>Kimball</surname> <given-names>EH</given-names></name><name><surname>Gao</surname> <given-names>M</given-names></name><name><surname>Osterhout</surname> <given-names>R</given-names></name><name><surname>Van Dien</surname> <given-names>SJ</given-names></name><name><surname>Rabinowitz</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Absolute metabolite concentrations and implied enzyme active site occupancy in Escherichia coli</article-title><source>Nature Chemical Biology</source><volume>5</volume><fpage>593</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1038/nchembio.186</pub-id><pub-id pub-id-type="pmid">19561621</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bensinger</surname> <given-names>SJ</given-names></name><name><surname>Tontonoz</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Integration of metabolism and inflammation by lipid-activated nuclear receptors</article-title><source>Nature</source><volume>454</volume><fpage>470</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1038/nature07202</pub-id><pub-id pub-id-type="pmid">18650918</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blewett</surname> <given-names>MM</given-names></name><name><surname>Xie</surname> <given-names>J</given-names></name><name><surname>Zaro</surname> <given-names>BW</given-names></name><name><surname>Backus</surname> <given-names>KM</given-names></name><name><surname>Altman</surname> <given-names>A</given-names></name><name><surname>Teijaro</surname> <given-names>JR</given-names></name><name><surname>Cravatt</surname> <given-names>BF</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Chemical proteomic map of dimethyl fumarate-sensitive cysteines in primary human T cells</article-title><source>Science Signaling</source><volume>9</volume><elocation-id>rs10</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aaf7694</pub-id><pub-id pub-id-type="pmid">27625306</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brand</surname> <given-names>K</given-names></name><name><surname>Williams</surname> <given-names>JF</given-names></name><name><surname>Weidemann</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="1984">1984</year><article-title>Glucose and glutamine metabolism in rat thymocytes</article-title><source>Biochemical Journal</source><volume>221</volume><fpage>471</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1042/bj2210471</pub-id><pub-id pub-id-type="pmid">6332620</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buck</surname> <given-names>MD</given-names></name><name><surname>Sowell</surname> <given-names>RT</given-names></name><name><surname>Kaech</surname> <given-names>SM</given-names></name><name><surname>Pearce</surname> <given-names>EL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Metabolic Instruction of Immunity</article-title><source>Cell</source><volume>169</volume><fpage>570</fpage><lpage>586</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.04.004</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Shertzer</surname> <given-names>HG</given-names></name><name><surname>Schneider</surname> <given-names>SN</given-names></name><name><surname>Nebert</surname> <given-names>DW</given-names></name><name><surname>Dalton</surname> <given-names>TP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Glutamate cysteine ligase catalysis: dependence on ATP and modifier subunit for regulation of tissue glutathione levels</article-title><source>The Journal of Biological Chemistry</source><volume>280</volume><fpage>33766</fpage><lpage>33774</lpage><pub-id pub-id-type="doi">10.1074/jbc.M504604200</pub-id><pub-id pub-id-type="pmid">16081425</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Yang</surname> <given-names>Y</given-names></name><name><surname>Miller</surname> <given-names>ML</given-names></name><name><surname>Shen</surname> <given-names>D</given-names></name><name><surname>Shertzer</surname> <given-names>HG</given-names></name><name><surname>Stringer</surname> <given-names>KF</given-names></name><name><surname>Wang</surname> <given-names>B</given-names></name><name><surname>Schneider</surname> <given-names>SN</given-names></name><name><surname>Nebert</surname> <given-names>DW</given-names></name><name><surname>Dalton</surname> <given-names>TP</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Hepatocyte-specific <italic>gclc</italic> deletion leads to rapid onset of steatosis with mitochondrial injury and liver failure</article-title><source>Hepatology</source><volume>45</volume><fpage>1118</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.1002/hep.21635</pub-id><pub-id pub-id-type="pmid">17464988</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>H</given-names></name><name><surname>Assmann</surname> <given-names>JC</given-names></name><name><surname>Krenz</surname> <given-names>A</given-names></name><name><surname>Rahman</surname> <given-names>M</given-names></name><name><surname>Grimm</surname> <given-names>M</given-names></name><name><surname>Karsten</surname> <given-names>CM</given-names></name><name><surname>Köhl</surname> <given-names>J</given-names></name><name><surname>Offermanns</surname> <given-names>S</given-names></name><name><surname>Wettschureck</surname> <given-names>N</given-names></name><name><surname>Schwaninger</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE</article-title><source>Journal of Clinical Investigation</source><volume>124</volume><fpage>2188</fpage><lpage>2192</lpage><pub-id pub-id-type="doi">10.1172/JCI72151</pub-id><pub-id pub-id-type="pmid">24691444</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chi</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Regulation and function of mTOR signalling in T cell fate decisions</article-title><source>Nature Reviews Immunology</source><volume>12</volume><fpage>325</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1038/nri3198</pub-id><pub-id pub-id-type="pmid">22517423</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>CONFIRM Study Investigators</collab><name><surname>Fox</surname> <given-names>RJ</given-names></name><name><surname>Miller</surname> <given-names>DH</given-names></name><name><surname>Phillips</surname> <given-names>JT</given-names></name><name><surname>Hutchinson</surname> <given-names>M</given-names></name><name><surname>Havrdova</surname> <given-names>E</given-names></name><name><surname>Kita</surname> <given-names>M</given-names></name><name><surname>Yang</surname> <given-names>M</given-names></name><name><surname>Raghupathi</surname> <given-names>K</given-names></name><name><surname>Novas</surname> <given-names>M</given-names></name><name><surname>Sweetser</surname> <given-names>MT</given-names></name><name><surname>Viglietta</surname> <given-names>V</given-names></name><name><surname>Dawson</surname> <given-names>KT</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis</article-title><source>New England Journal of Medicine</source><volume>367</volume><fpage>1087</fpage><lpage>1097</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1206328</pub-id><pub-id pub-id-type="pmid">22992072</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cossarizza</surname> <given-names>A</given-names></name><name><surname>Ferraresi</surname> <given-names>R</given-names></name><name><surname>Troiano</surname> <given-names>L</given-names></name><name><surname>Roat</surname> <given-names>E</given-names></name><name><surname>Gibellini</surname> <given-names>L</given-names></name><name><surname>Bertoncelli</surname> <given-names>L</given-names></name><name><surname>Nasi</surname> <given-names>M</given-names></name><name><surname>Pinti</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Simultaneous analysis of reactive oxygen species and reduced glutathione content in living cells by polychromatic flow cytometry</article-title><source>Nature Protocols</source><volume>4</volume><fpage>1790</fpage><lpage>1797</lpage><pub-id pub-id-type="doi">10.1038/nprot.2009.189</pub-id><pub-id pub-id-type="pmid">20010930</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cotgreave</surname> <given-names>IA</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>N-acetylcysteine: pharmacological considerations and experimental and clinical applications</article-title><source>Advances in Pharmacology</source><volume>38</volume><fpage>205</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1016/S1054-3589(08)60985-0</pub-id><pub-id pub-id-type="pmid">8895810</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Couto</surname> <given-names>N</given-names></name><name><surname>Wood</surname> <given-names>J</given-names></name><name><surname>Barber</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The role of glutathione reductase and related enzymes on cellular redox homoeostasis network</article-title><source>Free Radical Biology and Medicine</source><volume>95</volume><fpage>27</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2016.02.028</pub-id><pub-id pub-id-type="pmid">26923386</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dang</surname> <given-names>EV</given-names></name><name><surname>Barbi</surname> <given-names>J</given-names></name><name><surname>Yang</surname> <given-names>HY</given-names></name><name><surname>Jinasena</surname> <given-names>D</given-names></name><name><surname>Yu</surname> <given-names>H</given-names></name><name><surname>Zheng</surname> <given-names>Y</given-names></name><name><surname>Bordman</surname> <given-names>Z</given-names></name><name><surname>Fu</surname> <given-names>J</given-names></name><name><surname>Kim</surname> <given-names>Y</given-names></name><name><surname>Yen</surname> <given-names>HR</given-names></name><name><surname>Luo</surname> <given-names>W</given-names></name><name><surname>Zeller</surname> <given-names>K</given-names></name><name><surname>Shimoda</surname> <given-names>L</given-names></name><name><surname>Topalian</surname> <given-names>SL</given-names></name><name><surname>Semenza</surname> <given-names>GL</given-names></name><name><surname>Dang</surname> <given-names>CV</given-names></name><name><surname>Pardoll</surname> <given-names>DM</given-names></name><name><surname>Pan</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1</article-title><source>Cell</source><volume>146</volume><fpage>772</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.07.033</pub-id><pub-id pub-id-type="pmid">21871655</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Luca</surname> <given-names>C</given-names></name><name><surname>Kowalski</surname> <given-names>TJ</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Elmquist</surname> <given-names>JK</given-names></name><name><surname>Lee</surname> <given-names>C</given-names></name><name><surname>Kilimann</surname> <given-names>MW</given-names></name><name><surname>Ludwig</surname> <given-names>T</given-names></name><name><surname>Liu</surname> <given-names>SM</given-names></name><name><surname>Chua</surname> <given-names>SC</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Complete rescue of obesity, diabetes, and infertility in db/db mice by neuron-specific LEPR-B transgenes</article-title><source>Journal of Clinical Investigation</source><volume>115</volume><fpage>3484</fpage><lpage>3493</lpage><pub-id pub-id-type="doi">10.1172/JCI24059</pub-id><pub-id pub-id-type="pmid">16284652</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>DEFINE Study Investigators</collab><name><surname>Gold</surname> <given-names>R</given-names></name><name><surname>Kappos</surname> <given-names>L</given-names></name><name><surname>Arnold</surname> <given-names>DL</given-names></name><name><surname>Bar-Or</surname> <given-names>A</given-names></name><name><surname>Giovannoni</surname> <given-names>G</given-names></name><name><surname>Selmaj</surname> <given-names>K</given-names></name><name><surname>Tornatore</surname> <given-names>C</given-names></name><name><surname>Sweetser</surname> <given-names>MT</given-names></name><name><surname>Yang</surname> <given-names>M</given-names></name><name><surname>Sheikh</surname> <given-names>SI</given-names></name><name><surname>Dawson</surname> <given-names>KT</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis</article-title><source>New England Journal of Medicine</source><volume>367</volume><fpage>1098</fpage><lpage>1107</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1114287</pub-id><pub-id pub-id-type="pmid">22992073</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname> <given-names>Y</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Lu</surname> <given-names>J</given-names></name><name><surname>Holmgren</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Glutathione and glutaredoxin act as a backup of human thioredoxin reductase 1 to reduce thioredoxin 1 preventing cell death by aurothioglucose</article-title><source>Journal of Biological Chemistry</source><volume>287</volume><fpage>38210</fpage><lpage>38219</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.392225</pub-id><pub-id pub-id-type="pmid">22977247</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duffy</surname> <given-names>S</given-names></name><name><surname>So</surname> <given-names>A</given-names></name><name><surname>Murphy</surname> <given-names>TH</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Activation of endogenous antioxidant defenses in neuronal cells prevents free radical-mediated damage</article-title><source>Journal of Neurochemistry</source><volume>71</volume><fpage>69</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.1998.71010069.x</pub-id><pub-id pub-id-type="pmid">9648852</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Fan</surname> <given-names>T</given-names></name><name><surname>Lane</surname> <given-names>AN</given-names></name><name><surname>Higashi</surname> <given-names>RM</given-names></name></person-group><year iso-8601-date="2012">2012</year><source>The Handbook of Metabolomics</source><pub-id pub-id-type="doi">10.1007/978-1-61779-618-0</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname> <given-names>TW</given-names></name><name><surname>Warmoes</surname> <given-names>MO</given-names></name><name><surname>Sun</surname> <given-names>Q</given-names></name><name><surname>Song</surname> <given-names>H</given-names></name><name><surname>Turchan-Cholewo</surname> <given-names>J</given-names></name><name><surname>Martin</surname> <given-names>JT</given-names></name><name><surname>Mahan</surname> <given-names>A</given-names></name><name><surname>Higashi</surname> <given-names>RM</given-names></name><name><surname>Lane</surname> <given-names>AN</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Distinctly perturbed metabolic networks underlie differential tumor tissue damages induced by immune modulator β-glucan in a two-case ex vivo non-small cell lung Cancer study</article-title><source>Cold Spring Harbor Molecular Case Studies</source><volume>2</volume><elocation-id>a000893</elocation-id><pub-id pub-id-type="doi">10.1101/mcs.a000893</pub-id><pub-id pub-id-type="pmid">27551682</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finlay</surname> <given-names>D</given-names></name><name><surname>Cantrell</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Metabolism, migration and memory in cytotoxic T cells</article-title><source>Nature Reviews Immunology</source><volume>11</volume><fpage>109</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1038/nri2888</pub-id><pub-id pub-id-type="pmid">21233853</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finlay</surname> <given-names>DK</given-names></name><name><surname>Rosenzweig</surname> <given-names>E</given-names></name><name><surname>Sinclair</surname> <given-names>LV</given-names></name><name><surname>Feijoo-Carnero</surname> <given-names>C</given-names></name><name><surname>Hukelmann</surname> <given-names>JL</given-names></name><name><surname>Rolf</surname> <given-names>J</given-names></name><name><surname>Panteleyev</surname> <given-names>AA</given-names></name><name><surname>Okkenhaug</surname> <given-names>K</given-names></name><name><surname>Cantrell</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8<sup>+</sup> T cells</article-title><source>The Journal of Experimental Medicine</source><volume>209</volume><fpage>2441</fpage><lpage>2453</lpage><pub-id pub-id-type="doi">10.1084/jem.20112607</pub-id><pub-id pub-id-type="pmid">23183047</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franklin</surname> <given-names>CC</given-names></name><name><surname>Backos</surname> <given-names>DS</given-names></name><name><surname>Mohar</surname> <given-names>I</given-names></name><name><surname>White</surname> <given-names>CC</given-names></name><name><surname>Forman</surname> <given-names>HJ</given-names></name><name><surname>Kavanagh</surname> <given-names>TJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Structure, function, and post-translational regulation of the catalytic and modifier subunits of glutamate cysteine ligase</article-title><source>Molecular Aspects of Medicine</source><volume>30</volume><fpage>86</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/j.mam.2008.08.009</pub-id><pub-id pub-id-type="pmid">18812186</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frauwirth</surname> <given-names>KA</given-names></name><name><surname>Riley</surname> <given-names>JL</given-names></name><name><surname>Harris</surname> <given-names>MH</given-names></name><name><surname>Parry</surname> <given-names>RV</given-names></name><name><surname>Rathmell</surname> <given-names>JC</given-names></name><name><surname>Plas</surname> <given-names>DR</given-names></name><name><surname>Elstrom</surname> <given-names>RL</given-names></name><name><surname>June</surname> <given-names>CH</given-names></name><name><surname>Thompson</surname> <given-names>CB</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The CD28 signaling pathway regulates glucose metabolism</article-title><source>Immunity</source><volume>16</volume><fpage>769</fpage><lpage>777</lpage><pub-id pub-id-type="doi">10.1016/S1074-7613(02)00323-0</pub-id><pub-id pub-id-type="pmid">12121659</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganguly</surname> <given-names>D</given-names></name><name><surname>Srikanth</surname> <given-names>CV</given-names></name><name><surname>Kumar</surname> <given-names>C</given-names></name><name><surname>Vats</surname> <given-names>P</given-names></name><name><surname>Bachhawat</surname> <given-names>AK</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Why is glutathione (a tripeptide) synthesized by specific enzymes while TSH releasing hormone (TRH or thyroliberin), also a tripeptide, is produced as part of a prohormone protein?</article-title><source>IUBMB Life</source><volume>55</volume><fpage>553</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1080/15216540310001623064</pub-id><pub-id pub-id-type="pmid">14658762</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerriets</surname> <given-names>VA</given-names></name><name><surname>Kishton</surname> <given-names>RJ</given-names></name><name><surname>Nichols</surname> <given-names>AG</given-names></name><name><surname>Macintyre</surname> <given-names>AN</given-names></name><name><surname>Inoue</surname> <given-names>M</given-names></name><name><surname>Ilkayeva</surname> <given-names>O</given-names></name><name><surname>Winter</surname> <given-names>PS</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Priyadharshini</surname> <given-names>B</given-names></name><name><surname>Slawinska</surname> <given-names>ME</given-names></name><name><surname>Haeberli</surname> <given-names>L</given-names></name><name><surname>Huck</surname> <given-names>C</given-names></name><name><surname>Turka</surname> <given-names>LA</given-names></name><name><surname>Wood</surname> <given-names>KC</given-names></name><name><surname>Hale</surname> <given-names>LP</given-names></name><name><surname>Smith</surname> <given-names>PA</given-names></name><name><surname>Schneider</surname> <given-names>MA</given-names></name><name><surname>MacIver</surname> <given-names>NJ</given-names></name><name><surname>Locasale</surname> <given-names>JW</given-names></name><name><surname>Newgard</surname> <given-names>CB</given-names></name><name><surname>Shinohara</surname> <given-names>ML</given-names></name><name><surname>Rathmell</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation</article-title><source>Journal of Clinical Investigation</source><volume>125</volume><fpage>194</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1172/JCI76012</pub-id><pub-id pub-id-type="pmid">25437876</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerriets</surname> <given-names>VA</given-names></name><name><surname>Rathmell</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Metabolic pathways in T cell fate and function</article-title><source>Trends in Immunology</source><volume>33</volume><fpage>168</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1016/j.it.2012.01.010</pub-id><pub-id pub-id-type="pmid">22342741</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gill</surname> <given-names>AJ</given-names></name><name><surname>Kolson</surname> <given-names>DL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy</article-title><source>Critical Reviews in Immunology</source><volume>33</volume><fpage>307</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1615/CritRevImmunol.2013007247</pub-id><pub-id pub-id-type="pmid">23971529</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorrini</surname> <given-names>C</given-names></name><name><surname>Harris</surname> <given-names>IS</given-names></name><name><surname>Mak</surname> <given-names>TW</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Modulation of oxidative stress as an anticancer strategy</article-title><source>Nature Reviews Drug Discovery</source><volume>12</volume><fpage>931</fpage><lpage>947</lpage><pub-id pub-id-type="doi">10.1038/nrd4002</pub-id><pub-id pub-id-type="pmid">24287781</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanschmann</surname> <given-names>EM</given-names></name><name><surname>Lönn</surname> <given-names>ME</given-names></name><name><surname>Schütte</surname> <given-names>LD</given-names></name><name><surname>Funke</surname> <given-names>M</given-names></name><name><surname>Godoy</surname> <given-names>JR</given-names></name><name><surname>Eitner</surname> <given-names>S</given-names></name><name><surname>Hudemann</surname> <given-names>C</given-names></name><name><surname>Lillig</surname> <given-names>CH</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Both thioredoxin 2 and glutaredoxin 2 contribute to the reduction of the mitochondrial 2-Cys peroxiredoxin Prx3</article-title><source>Journal of Biological Chemistry</source><volume>285</volume><fpage>40699</fpage><lpage>40705</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.185827</pub-id><pub-id pub-id-type="pmid">20929858</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hensley</surname> <given-names>CT</given-names></name><name><surname>Wasti</surname> <given-names>AT</given-names></name><name><surname>DeBerardinis</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Glutamine and Cancer: cell biology, physiology, and clinical opportunities</article-title><source>Journal of Clinical Investigation</source><volume>123</volume><fpage>3678</fpage><lpage>3684</lpage><pub-id pub-id-type="doi">10.1172/JCI69600</pub-id><pub-id pub-id-type="pmid">23999442</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname> <given-names>PC</given-names></name><name><surname>Bihuniak</surname> <given-names>JD</given-names></name><name><surname>Macintyre</surname> <given-names>AN</given-names></name><name><surname>Staron</surname> <given-names>M</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Amezquita</surname> <given-names>R</given-names></name><name><surname>Tsui</surname> <given-names>YC</given-names></name><name><surname>Cui</surname> <given-names>G</given-names></name><name><surname>Micevic</surname> <given-names>G</given-names></name><name><surname>Perales</surname> <given-names>JC</given-names></name><name><surname>Kleinstein</surname> <given-names>SH</given-names></name><name><surname>Abel</surname> <given-names>ED</given-names></name><name><surname>Insogna</surname> <given-names>KL</given-names></name><name><surname>Feske</surname> <given-names>S</given-names></name><name><surname>Locasale</surname> <given-names>JW</given-names></name><name><surname>Bosenberg</surname> <given-names>MW</given-names></name><name><surname>Rathmell</surname> <given-names>JC</given-names></name><name><surname>Kaech</surname> <given-names>SM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Phosphoenolpyruvate is a metabolic checkpoint of Anti-tumor T cell responses</article-title><source>Cell</source><volume>162</volume><fpage>1217</fpage><lpage>1228</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.08.012</pub-id><pub-id pub-id-type="pmid">26321681</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname> <given-names>C</given-names></name><name><surname>Sinskey</surname> <given-names>AJ</given-names></name><name><surname>Lodish</surname> <given-names>HF</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Oxidized redox state of glutathione in the endoplasmic reticulum</article-title><source>Science</source><volume>257</volume><fpage>1496</fpage><lpage>1502</lpage><pub-id pub-id-type="doi">10.1126/science.1523409</pub-id><pub-id pub-id-type="pmid">1523409</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname> <given-names>SH</given-names></name><name><surname>Devadas</surname> <given-names>S</given-names></name><name><surname>Kwon</surname> <given-names>J</given-names></name><name><surname>Pinto</surname> <given-names>LA</given-names></name><name><surname>Williams</surname> <given-names>MS</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>T cells express a phagocyte-type NADPH oxidase that is activated after T cell receptor stimulation</article-title><source>Nature Immunology</source><volume>5</volume><fpage>818</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.1038/ni1096</pub-id><pub-id pub-id-type="pmid">15258578</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobs</surname> <given-names>SR</given-names></name><name><surname>Herman</surname> <given-names>CE</given-names></name><name><surname>Maciver</surname> <given-names>NJ</given-names></name><name><surname>Wofford</surname> <given-names>JA</given-names></name><name><surname>Wieman</surname> <given-names>HL</given-names></name><name><surname>Hammen</surname> <given-names>JJ</given-names></name><name><surname>Rathmell</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways</article-title><source>The Journal of Immunology</source><volume>180</volume><fpage>4476</fpage><lpage>4486</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.180.7.4476</pub-id><pub-id pub-id-type="pmid">18354169</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaramillo</surname> <given-names>MC</given-names></name><name><surname>Zhang</surname> <given-names>DD</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The emerging role of the Nrf2-Keap1 signaling pathway in Cancer</article-title><source>Genes &amp; Development</source><volume>27</volume><fpage>2179</fpage><lpage>2191</lpage><pub-id pub-id-type="doi">10.1101/gad.225680.113</pub-id><pub-id pub-id-type="pmid">24142871</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johansson</surname> <given-names>C</given-names></name><name><surname>Lillig</surname> <given-names>CH</given-names></name><name><surname>Holmgren</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Human mitochondrial glutaredoxin reduces S-glutathionylated proteins with high affinity accepting electrons from either glutathione or thioredoxin reductase</article-title><source>Journal of Biological Chemistry</source><volume>279</volume><fpage>7537</fpage><lpage>7543</lpage><pub-id pub-id-type="doi">10.1074/jbc.M312719200</pub-id><pub-id pub-id-type="pmid">14676218</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamiński</surname> <given-names>MM</given-names></name><name><surname>Sauer</surname> <given-names>SW</given-names></name><name><surname>Kamiński</surname> <given-names>M</given-names></name><name><surname>Opp</surname> <given-names>S</given-names></name><name><surname>Ruppert</surname> <given-names>T</given-names></name><name><surname>Grigaravičius</surname> <given-names>P</given-names></name><name><surname>Grudnik</surname> <given-names>P</given-names></name><name><surname>Gröne</surname> <given-names>HJ</given-names></name><name><surname>Krammer</surname> <given-names>PH</given-names></name><name><surname>Gülow</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>T cell activation is driven by an ADP-dependent glucokinase linking enhanced glycolysis with mitochondrial reactive oxygen species generation</article-title><source>Cell Reports</source><volume>2</volume><fpage>1300</fpage><lpage>1315</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2012.10.009</pub-id><pub-id pub-id-type="pmid">23168256</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamiński</surname> <given-names>MM</given-names></name><name><surname>Röth</surname> <given-names>D</given-names></name><name><surname>Krammer</surname> <given-names>PH</given-names></name><name><surname>Gülow</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mitochondria as oxidative signaling organelles in T-cell activation: physiological role and pathological implications</article-title><source>Archivum Immunologiae Et Therapiae Experimentalis</source><volume>61</volume><fpage>367</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1007/s00005-013-0235-0</pub-id><pub-id pub-id-type="pmid">23749029</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname> <given-names>Z</given-names></name><name><surname>Altuntas</surname> <given-names>CZ</given-names></name><name><surname>Gulen</surname> <given-names>MF</given-names></name><name><surname>Liu</surname> <given-names>C</given-names></name><name><surname>Giltiay</surname> <given-names>N</given-names></name><name><surname>Qin</surname> <given-names>H</given-names></name><name><surname>Liu</surname> <given-names>L</given-names></name><name><surname>Qian</surname> <given-names>W</given-names></name><name><surname>Ransohoff</surname> <given-names>RM</given-names></name><name><surname>Bergmann</surname> <given-names>C</given-names></name><name><surname>Stohlman</surname> <given-names>S</given-names></name><name><surname>Tuohy</surname> <given-names>VK</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis</article-title><source>Immunity</source><volume>32</volume><fpage>414</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2010.03.004</pub-id><pub-id pub-id-type="pmid">20303295</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kees</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Dimethyl fumarate : a Janus-faced substance?</article-title><source>Expert Opinion on Pharmacotherapy</source><volume>14</volume><fpage>1559</fpage><lpage>1567</lpage><pub-id pub-id-type="doi">10.1517/14656566.2013.804912</pub-id><pub-id pub-id-type="pmid">23697607</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein Geltink</surname> <given-names>RI</given-names></name><name><surname>O'Sullivan</surname> <given-names>D</given-names></name><name><surname>Pearce</surname> <given-names>EL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Caught in the cROSsfire: gsh controls T cell metabolic reprogramming</article-title><source>Immunity</source><volume>46</volume><fpage>525</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2017.03.022</pub-id><pub-id pub-id-type="pmid">28423332</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klysz</surname> <given-names>D</given-names></name><name><surname>Tai</surname> <given-names>X</given-names></name><name><surname>Robert</surname> <given-names>PA</given-names></name><name><surname>Craveiro</surname> <given-names>M</given-names></name><name><surname>Cretenet</surname> <given-names>G</given-names></name><name><surname>Oburoglu</surname> <given-names>L</given-names></name><name><surname>Mongellaz</surname> <given-names>C</given-names></name><name><surname>Floess</surname> <given-names>S</given-names></name><name><surname>Fritz</surname> <given-names>V</given-names></name><name><surname>Matias</surname> <given-names>MI</given-names></name><name><surname>Yong</surname> <given-names>C</given-names></name><name><surname>Surh</surname> <given-names>N</given-names></name><name><surname>Marie</surname> <given-names>JC</given-names></name><name><surname>Huehn</surname> <given-names>J</given-names></name><name><surname>Zimmermann</surname> <given-names>V</given-names></name><name><surname>Kinet</surname> <given-names>S</given-names></name><name><surname>Dardalhon</surname> <given-names>V</given-names></name><name><surname>Taylor</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Glutamine-dependent α-ketoglutarate production regulates the balance between T helper 1 cell and regulatory T cell generation</article-title><source>Science Signaling</source><volume>8</volume><elocation-id>ra97</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aab2610</pub-id><pub-id pub-id-type="pmid">26420908</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kosower</surname> <given-names>NS</given-names></name><name><surname>Kosower</surname> <given-names>EM</given-names></name></person-group><year iso-8601-date="1978">1978</year><article-title>The glutathione status of cells</article-title><source>International Review of Cytology</source><volume>54</volume><fpage>109</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1016/S0074-7696(08)60166-7</pub-id><pub-id pub-id-type="pmid">42630</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lane</surname> <given-names>AN</given-names></name><name><surname>Fan</surname> <given-names>TW</given-names></name><name><surname>Higashi</surname> <given-names>RM</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Isotopomer-based metabolomic analysis by NMR and mass spectrometry</article-title><source>Methods in Cell Biology</source><volume>84</volume><fpage>541</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.1016/S0091-679X(07)84018-0</pub-id><pub-id pub-id-type="pmid">17964943</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname> <given-names>A</given-names></name><name><surname>Lane</surname> <given-names>AN</given-names></name><name><surname>Hamaker</surname> <given-names>M</given-names></name><name><surname>Bose</surname> <given-names>S</given-names></name><name><surname>Gouw</surname> <given-names>A</given-names></name><name><surname>Barbi</surname> <given-names>J</given-names></name><name><surname>Tsukamoto</surname> <given-names>T</given-names></name><name><surname>Rojas</surname> <given-names>CJ</given-names></name><name><surname>Slusher</surname> <given-names>BS</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Zimmerman</surname> <given-names>LJ</given-names></name><name><surname>Liebler</surname> <given-names>DC</given-names></name><name><surname>Slebos</surname> <given-names>RJ</given-names></name><name><surname>Lorkiewicz</surname> <given-names>PK</given-names></name><name><surname>Higashi</surname> <given-names>RM</given-names></name><name><surname>Fan</surname> <given-names>TW</given-names></name><name><surname>Dang</surname> <given-names>CV</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells</article-title><source>Cell Metabolism</source><volume>15</volume><fpage>110</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2011.12.009</pub-id><pub-id pub-id-type="pmid">22225880</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname> <given-names>XG</given-names></name><name><surname>Zhu</surname> <given-names>JH</given-names></name><name><surname>Cheng</surname> <given-names>WH</given-names></name><name><surname>Bao</surname> <given-names>Y</given-names></name><name><surname>Ho</surname> <given-names>YS</given-names></name><name><surname>Reddi</surname> <given-names>AR</given-names></name><name><surname>Holmgren</surname> <given-names>A</given-names></name><name><surname>Arnér</surname> <given-names>ES</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Paradoxical roles of antioxidant enzymes: basic mechanisms and health implications</article-title><source>Physiological Reviews</source><volume>96</volume><fpage>307</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1152/physrev.00010.2014</pub-id><pub-id pub-id-type="pmid">26681794</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linker</surname> <given-names>RA</given-names></name><name><surname>Gold</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects</article-title><source>Current Neurology and Neuroscience Reports</source><volume>13</volume><elocation-id>394</elocation-id><pub-id pub-id-type="doi">10.1007/s11910-013-0394-8</pub-id><pub-id pub-id-type="pmid">24061646</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname> <given-names>J</given-names></name><name><surname>Chew</surname> <given-names>EH</given-names></name><name><surname>Holmgren</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Targeting thioredoxin reductase is a basis for Cancer therapy by arsenic trioxide</article-title><source>PNAS</source><volume>104</volume><fpage>12288</fpage><lpage>12293</lpage><pub-id pub-id-type="doi">10.1073/pnas.0701549104</pub-id><pub-id pub-id-type="pmid">17640917</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname> <given-names>SC</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Regulation of glutathione synthesis</article-title><source>Molecular Aspects of Medicine</source><volume>30</volume><fpage>42</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.mam.2008.05.005</pub-id><pub-id pub-id-type="pmid">18601945</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname> <given-names>J</given-names></name><name><surname>Holmgren</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The thioredoxin antioxidant system</article-title><source>Free Radical Biology and Medicine</source><volume>66</volume><fpage>75</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2013.07.036</pub-id><pub-id pub-id-type="pmid">23899494</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname> <given-names>Q</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Role of nrf2 in oxidative stress and toxicity</article-title><source>Annual Review of Pharmacology and Toxicology</source><volume>53</volume><fpage>401</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1146/annurev-pharmtox-011112-140320</pub-id><pub-id pub-id-type="pmid">23294312</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname> <given-names>EH</given-names></name><name><surname>Poffenberger</surname> <given-names>MC</given-names></name><name><surname>Wong</surname> <given-names>AH</given-names></name><name><surname>Jones</surname> <given-names>RG</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The role of AMPK in T cell metabolism and function</article-title><source>Current Opinion in Immunology</source><volume>46</volume><fpage>45</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2017.04.004</pub-id><pub-id pub-id-type="pmid">28460345</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mak</surname> <given-names>TW</given-names></name><name><surname>Grusdat</surname> <given-names>M</given-names></name><name><surname>Duncan</surname> <given-names>GS</given-names></name><name><surname>Dostert</surname> <given-names>C</given-names></name><name><surname>Nonnenmacher</surname> <given-names>Y</given-names></name><name><surname>Cox</surname> <given-names>M</given-names></name><name><surname>Binsfeld</surname> <given-names>C</given-names></name><name><surname>Hao</surname> <given-names>Z</given-names></name><name><surname>Brüstle</surname> <given-names>A</given-names></name><name><surname>Itsumi</surname> <given-names>M</given-names></name><name><surname>Jäger</surname> <given-names>C</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Pinkenburg</surname> <given-names>O</given-names></name><name><surname>Camara</surname> <given-names>B</given-names></name><name><surname>Ollert</surname> <given-names>M</given-names></name><name><surname>Bindslev-Jensen</surname> <given-names>C</given-names></name><name><surname>Vasiliou</surname> <given-names>V</given-names></name><name><surname>Gorrini</surname> <given-names>C</given-names></name><name><surname>Lang</surname> <given-names>PA</given-names></name><name><surname>Lohoff</surname> <given-names>M</given-names></name><name><surname>Harris</surname> <given-names>IS</given-names></name><name><surname>Hiller</surname> <given-names>K</given-names></name><name><surname>Brenner</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Glutathione primes T cell metabolism for inflammation</article-title><source>Immunity</source><volume>46</volume><fpage>675</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2017.03.019</pub-id><pub-id pub-id-type="pmid">28423341</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandal</surname> <given-names>PK</given-names></name><name><surname>Schneider</surname> <given-names>M</given-names></name><name><surname>Kölle</surname> <given-names>P</given-names></name><name><surname>Kuhlencordt</surname> <given-names>P</given-names></name><name><surname>Förster</surname> <given-names>H</given-names></name><name><surname>Beck</surname> <given-names>H</given-names></name><name><surname>Bornkamm</surname> <given-names>GW</given-names></name><name><surname>Conrad</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Loss of thioredoxin reductase 1 renders tumors highly susceptible to pharmacologic glutathione deprivation</article-title><source>Cancer Research</source><volume>70</volume><fpage>9505</fpage><lpage>9514</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-1509</pub-id><pub-id pub-id-type="pmid">21045148</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massière</surname> <given-names>F</given-names></name><name><surname>Badet-Denisot</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>The mechanism of glutamine-dependent amidotransferases</article-title><source>Cellular and Molecular Life Sciences CMLS</source><volume>54</volume><fpage>205</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1007/s000180050145</pub-id><pub-id pub-id-type="pmid">9575335</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthias</surname> <given-names>LJ</given-names></name><name><surname>Yam</surname> <given-names>PT</given-names></name><name><surname>Jiang</surname> <given-names>XM</given-names></name><name><surname>Vandegraaff</surname> <given-names>N</given-names></name><name><surname>Li</surname> <given-names>P</given-names></name><name><surname>Poumbourios</surname> <given-names>P</given-names></name><name><surname>Donoghue</surname> <given-names>N</given-names></name><name><surname>Hogg</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Disulfide exchange in domain 2 of CD4 is required for entry of HIV-1</article-title><source>Nature Immunology</source><volume>3</volume><fpage>727</fpage><lpage>732</lpage><pub-id pub-id-type="doi">10.1038/ni815</pub-id><pub-id pub-id-type="pmid">12089508</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meister</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="1982">1982</year><article-title>Metabolism and function of glutathione: an overview</article-title><source>Biochemical Society Transactions</source><volume>10</volume><fpage>78</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1042/bst0100078</pub-id><pub-id pub-id-type="pmid">6121735</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michalek</surname> <given-names>RD</given-names></name><name><surname>Gerriets</surname> <given-names>VA</given-names></name><name><surname>Jacobs</surname> <given-names>SR</given-names></name><name><surname>Macintyre</surname> <given-names>AN</given-names></name><name><surname>MacIver</surname> <given-names>NJ</given-names></name><name><surname>Mason</surname> <given-names>EF</given-names></name><name><surname>Sullivan</surname> <given-names>SA</given-names></name><name><surname>Nichols</surname> <given-names>AG</given-names></name><name><surname>Rathmell</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets</article-title><source>The Journal of Immunology</source><volume>186</volume><fpage>3299</fpage><lpage>3303</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1003613</pub-id><pub-id pub-id-type="pmid">21317389</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michalek</surname> <given-names>RD</given-names></name><name><surname>Rathmell</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The metabolic life and times of a T-cell</article-title><source>Immunological Reviews</source><volume>236</volume><fpage>190</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2010.00911.x</pub-id><pub-id pub-id-type="pmid">20636818</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname> <given-names>EL</given-names></name><name><surname>Kelly</surname> <given-names>B</given-names></name><name><surname>O'Neill</surname> <given-names>LAJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Mitochondria are the powerhouses of immunity</article-title><source>Nature Immunology</source><volume>18</volume><fpage>488</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1038/ni.3704</pub-id><pub-id pub-id-type="pmid">28418387</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname> <given-names>B</given-names></name><name><surname>Sobotta</surname> <given-names>MC</given-names></name><name><surname>Dick</surname> <given-names>TP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Measuring E(GSH) and H2O2 with roGFP2-based redox probes</article-title><source>Free Radical Biology and Medicine</source><volume>51</volume><fpage>1943</fpage><lpage>1951</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2011.08.035</pub-id><pub-id pub-id-type="pmid">21964034</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moseley</surname> <given-names>HN</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Correcting for the effects of natural abundance in stable isotope resolved metabolomics experiments involving ultra-high resolution mass spectrometry</article-title><source>BMC Bioinformatics</source><volume>11</volume><elocation-id>139</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-11-139</pub-id><pub-id pub-id-type="pmid">20236542</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motohashi</surname> <given-names>H</given-names></name><name><surname>Yamamoto</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Nrf2-Keap1 defines a physiologically important stress response mechanism</article-title><source>Trends in Molecular Medicine</source><volume>10</volume><fpage>549</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2004.09.003</pub-id><pub-id pub-id-type="pmid">15519281</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mrowietz</surname> <given-names>U</given-names></name><name><surname>Altmeyer</surname> <given-names>P</given-names></name><name><surname>Bieber</surname> <given-names>T</given-names></name><name><surname>Röcken</surname> <given-names>M</given-names></name><name><surname>Schopf</surname> <given-names>RE</given-names></name><name><surname>Sterry</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Treatment of psoriasis with fumaric acid esters (Fumaderm)</article-title><source>Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG</source><volume>5</volume><fpage>716</fpage><lpage>717</lpage><pub-id pub-id-type="doi">10.1111/j.1610-0387.2007.06346.x</pub-id><pub-id pub-id-type="pmid">17659047</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname> <given-names>MP</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>How mitochondria produce reactive oxygen species</article-title><source>Biochemical Journal</source><volume>417</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1042/BJ20081386</pub-id><pub-id pub-id-type="pmid">19061483</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname> <given-names>MP</given-names></name><name><surname>Siegel</surname> <given-names>RM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mitochondrial ROS fire up T cell activation</article-title><source>Immunity</source><volume>38</volume><fpage>201</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.02.005</pub-id><pub-id pub-id-type="pmid">23438817</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mustacich</surname> <given-names>D</given-names></name><name><surname>Powis</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Thioredoxin reductase</article-title><source>Biochemical Journal</source><volume>346</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1042/bj3460001</pub-id><pub-id pub-id-type="pmid">10657232</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nathan</surname> <given-names>C</given-names></name><name><surname>Cunningham-Bussel</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Beyond oxidative stress: an immunologist's guide to reactive oxygen species</article-title><source>Nature Reviews Immunology</source><volume>13</volume><fpage>349</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1038/nri3423</pub-id><pub-id pub-id-type="pmid">23618831</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Neill</surname> <given-names>LA</given-names></name><name><surname>Kishton</surname> <given-names>RJ</given-names></name><name><surname>Rathmell</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A guide to immunometabolism for immunologists</article-title><source>Nature Reviews Immunology</source><volume>16</volume><fpage>553</fpage><lpage>565</lpage><pub-id pub-id-type="doi">10.1038/nri.2016.70</pub-id><pub-id pub-id-type="pmid">27396447</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Padgett</surname> <given-names>LE</given-names></name><name><surname>Tse</surname> <given-names>HM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>NADPH Oxidase-Derived superoxide provides a third signal for CD4 T cell effector responses</article-title><source>The Journal of Immunology</source><volume>197</volume><fpage>1733</fpage><lpage>1742</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1502581</pub-id><pub-id pub-id-type="pmid">27474077</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname> <given-names>JO</given-names></name><name><surname>Rubin</surname> <given-names>SA</given-names></name><name><surname>Xu</surname> <given-names>YF</given-names></name><name><surname>Amador-Noguez</surname> <given-names>D</given-names></name><name><surname>Fan</surname> <given-names>J</given-names></name><name><surname>Shlomi</surname> <given-names>T</given-names></name><name><surname>Rabinowitz</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Metabolite concentrations, fluxes and free energies imply efficient enzyme usage</article-title><source>Nature Chemical Biology</source><volume>12</volume><fpage>482</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1038/nchembio.2077</pub-id><pub-id pub-id-type="pmid">27159581</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname> <given-names>CH</given-names></name><name><surname>Powell</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Targeting T cell metabolism to regulate T cell activation, differentiation and function in disease</article-title><source>Current Opinion in Immunology</source><volume>46</volume><fpage>82</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2017.04.006</pub-id><pub-id pub-id-type="pmid">28521236</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearce</surname> <given-names>EL</given-names></name><name><surname>Walsh</surname> <given-names>MC</given-names></name><name><surname>Cejas</surname> <given-names>PJ</given-names></name><name><surname>Harms</surname> <given-names>GM</given-names></name><name><surname>Shen</surname> <given-names>H</given-names></name><name><surname>Wang</surname> <given-names>LS</given-names></name><name><surname>Jones</surname> <given-names>RG</given-names></name><name><surname>Choi</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Enhancing CD8 T-cell memory by modulating fatty acid metabolism</article-title><source>Nature</source><volume>460</volume><fpage>103</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1038/nature08097</pub-id><pub-id pub-id-type="pmid">19494812</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearce</surname> <given-names>EL</given-names></name><name><surname>Pearce</surname> <given-names>EJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Metabolic pathways in immune cell activation and quiescence</article-title><source>Immunity</source><volume>38</volume><fpage>633</fpage><lpage>643</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.04.005</pub-id><pub-id pub-id-type="pmid">23601682</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearce</surname> <given-names>EL</given-names></name><name><surname>Poffenberger</surname> <given-names>MC</given-names></name><name><surname>Chang</surname> <given-names>CH</given-names></name><name><surname>Jones</surname> <given-names>RG</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Fueling immunity: insights into metabolism and lymphocyte function</article-title><source>Science</source><volume>342</volume><elocation-id>1242454</elocation-id><pub-id pub-id-type="doi">10.1126/science.1242454</pub-id><pub-id pub-id-type="pmid">24115444</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname> <given-names>H</given-names></name><name><surname>Guerau-de-Arellano</surname> <given-names>M</given-names></name><name><surname>Mehta</surname> <given-names>VB</given-names></name><name><surname>Yang</surname> <given-names>Y</given-names></name><name><surname>Huss</surname> <given-names>DJ</given-names></name><name><surname>Papenfuss</surname> <given-names>TL</given-names></name><name><surname>Lovett-Racke</surname> <given-names>AE</given-names></name><name><surname>Racke</surname> <given-names>MK</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor κb (NF-κB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling</article-title><source>Journal of Biological Chemistry</source><volume>287</volume><fpage>28017</fpage><lpage>28026</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.383380</pub-id><pub-id pub-id-type="pmid">22733812</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perrone</surname> <given-names>GG</given-names></name><name><surname>Grant</surname> <given-names>CM</given-names></name><name><surname>Dawes</surname> <given-names>IW</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Genetic and environmental factors influencing glutathione homeostasis in <italic>Saccharomyces cerevisiae</italic></article-title><source>Molecular Biology of the Cell</source><volume>16</volume><fpage>218</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1091/mbc.e04-07-0560</pub-id><pub-id pub-id-type="pmid">15509654</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinkus</surname> <given-names>LM</given-names></name></person-group><year iso-8601-date="1977">1977</year><article-title>Glutamine binding sites</article-title><source>Methods in Enzymology</source><volume>46</volume><fpage>414</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1016/S0076-6879(77)46049-X</pub-id><pub-id pub-id-type="pmid">909432</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powell</surname> <given-names>JD</given-names></name><name><surname>Delgoffe</surname> <given-names>GM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism</article-title><source>Immunity</source><volume>33</volume><fpage>301</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2010.09.002</pub-id><pub-id pub-id-type="pmid">20870173</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pretsch</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Glutathione reductase activity deficiency in homozygous Gr1a1Neu mice does not cause haemolytic anaemia</article-title><source>Genetical Research</source><volume>73</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1017/S0016672398003590</pub-id><pub-id pub-id-type="pmid">10218442</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purushothaman</surname> <given-names>D</given-names></name><name><surname>Sarin</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Cytokine-dependent regulation of NADPH oxidase activity and the consequences for activated T cell homeostasis</article-title><source>The Journal of Experimental Medicine</source><volume>206</volume><fpage>1515</fpage><lpage>1523</lpage><pub-id pub-id-type="doi">10.1084/jem.20082851</pub-id><pub-id pub-id-type="pmid">19546249</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rashida Gnanaprakasam</surname> <given-names>JN</given-names></name><name><surname>Wu</surname> <given-names>R</given-names></name><name><surname>Wang</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Metabolic reprogramming in modulating T cell reactive oxygen species generation and antioxidant capacity</article-title><source>Frontiers in Immunology</source><volume>9</volume><elocation-id>1075</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.01075</pub-id><pub-id pub-id-type="pmid">29868027</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogers</surname> <given-names>LK</given-names></name><name><surname>Tamura</surname> <given-names>T</given-names></name><name><surname>Rogers</surname> <given-names>BJ</given-names></name><name><surname>Welty</surname> <given-names>SE</given-names></name><name><surname>Hansen</surname> <given-names>TN</given-names></name><name><surname>Smith</surname> <given-names>CV</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Analyses of glutathione reductase hypomorphic mice indicate a genetic knockout</article-title><source>Toxicological Sciences</source><volume>82</volume><fpage>367</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1093/toxsci/kfh268</pub-id><pub-id pub-id-type="pmid">15342956</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosen</surname> <given-names>A</given-names></name><name><surname>Lundman</surname> <given-names>P</given-names></name><name><surname>Carlsson</surname> <given-names>M</given-names></name><name><surname>Bhavani</surname> <given-names>K</given-names></name><name><surname>Srinivasa</surname> <given-names>BR</given-names></name><name><surname>Kjellström</surname> <given-names>G</given-names></name><name><surname>Nilsson</surname> <given-names>K</given-names></name><name><surname>Holmgren</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>A CD4+ T cell line-secreted factor, growth promoting for normal and leukemic B cells, identified as thioredoxin</article-title><source>International Immunology</source><volume>7</volume><fpage>625</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.1093/intimm/7.4.625</pub-id><pub-id pub-id-type="pmid">7547690</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryan</surname> <given-names>HE</given-names></name><name><surname>Poloni</surname> <given-names>M</given-names></name><name><surname>McNulty</surname> <given-names>W</given-names></name><name><surname>Elson</surname> <given-names>D</given-names></name><name><surname>Gassmann</surname> <given-names>M</given-names></name><name><surname>Arbeit</surname> <given-names>JM</given-names></name><name><surname>Johnson</surname> <given-names>RS</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth</article-title><source>Cancer Research</source><volume>60</volume><fpage>4010</fpage><lpage>4015</lpage><pub-id pub-id-type="pmid">10945599</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schieber</surname> <given-names>M</given-names></name><name><surname>Chandel</surname> <given-names>NS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>ROS function in redox signaling and oxidative stress</article-title><source>Current Biology</source><volume>24</volume><fpage>R453</fpage><lpage>R462</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2014.03.034</pub-id><pub-id pub-id-type="pmid">24845678</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulze-Topphoff</surname> <given-names>U</given-names></name><name><surname>Varrin-Doyer</surname> <given-names>M</given-names></name><name><surname>Pekarek</surname> <given-names>K</given-names></name><name><surname>Spencer</surname> <given-names>CM</given-names></name><name><surname>Shetty</surname> <given-names>A</given-names></name><name><surname>Sagan</surname> <given-names>SA</given-names></name><name><surname>Cree</surname> <given-names>BA</given-names></name><name><surname>Sobel</surname> <given-names>RA</given-names></name><name><surname>Wipke</surname> <given-names>BT</given-names></name><name><surname>Steinman</surname> <given-names>L</given-names></name><name><surname>Scannevin</surname> <given-names>RH</given-names></name><name><surname>Zamvil</surname> <given-names>SS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2</article-title><source>PNAS</source><volume>113</volume><fpage>4777</fpage><lpage>4782</lpage><pub-id pub-id-type="doi">10.1073/pnas.1603907113</pub-id><pub-id pub-id-type="pmid">27078105</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sena</surname> <given-names>LA</given-names></name><name><surname>Li</surname> <given-names>S</given-names></name><name><surname>Jairaman</surname> <given-names>A</given-names></name><name><surname>Prakriya</surname> <given-names>M</given-names></name><name><surname>Ezponda</surname> <given-names>T</given-names></name><name><surname>Hildeman</surname> <given-names>DA</given-names></name><name><surname>Wang</surname> <given-names>CR</given-names></name><name><surname>Schumacker</surname> <given-names>PT</given-names></name><name><surname>Licht</surname> <given-names>JD</given-names></name><name><surname>Perlman</surname> <given-names>H</given-names></name><name><surname>Bryce</surname> <given-names>PJ</given-names></name><name><surname>Chandel</surname> <given-names>NS</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling</article-title><source>Immunity</source><volume>38</volume><fpage>225</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2012.10.020</pub-id><pub-id pub-id-type="pmid">23415911</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shapiro</surname> <given-names>RA</given-names></name><name><surname>Clark</surname> <given-names>VM</given-names></name><name><surname>Curthoys</surname> <given-names>NP</given-names></name></person-group><year iso-8601-date="1979">1979</year><article-title>Inactivation of rat renal phosphate-dependent glutaminase with 6-diazo-5-oxo-L-norleucine. evidence for interaction at the glutamine binding site</article-title><source>The Journal of Biological Chemistry</source><volume>254</volume><fpage>2835</fpage><lpage>2838</lpage><pub-id pub-id-type="pmid">429321</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname> <given-names>LZ</given-names></name><name><surname>Wang</surname> <given-names>R</given-names></name><name><surname>Huang</surname> <given-names>G</given-names></name><name><surname>Vogel</surname> <given-names>P</given-names></name><name><surname>Neale</surname> <given-names>G</given-names></name><name><surname>Green</surname> <given-names>DR</given-names></name><name><surname>Chi</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and treg cells</article-title><source>The Journal of Experimental Medicine</source><volume>208</volume><fpage>1367</fpage><lpage>1376</lpage><pub-id pub-id-type="doi">10.1084/jem.20110278</pub-id><pub-id pub-id-type="pmid">21708926</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simeoni</surname> <given-names>L</given-names></name><name><surname>Thurm</surname> <given-names>C</given-names></name><name><surname>Kritikos</surname> <given-names>A</given-names></name><name><surname>Linkermann</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Redox homeostasis, T cells and kidney diseases: three faces in the dark</article-title><source>Clinical Kidney Journal</source><volume>9</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1093/ckj/sfv135</pub-id><pub-id pub-id-type="pmid">26798455</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spandidos</surname> <given-names>A</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Seed</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>PrimerBank: a resource of human and mouse PCR primer pairs for gene expression detection and quantification</article-title><source>Nucleic Acids Research</source><volume>38</volume><fpage>D792</fpage><lpage>D799</lpage><pub-id pub-id-type="doi">10.1093/nar/gkp1005</pub-id><pub-id pub-id-type="pmid">19906719</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sporn</surname> <given-names>MB</given-names></name><name><surname>Liby</surname> <given-names>KT</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>NRF2 and Cancer: the good, the bad and the importance of context</article-title><source>Nature Reviews Cancer</source><volume>12</volume><fpage>564</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1038/nrc3278</pub-id><pub-id pub-id-type="pmid">22810811</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stockwell</surname> <given-names>BR</given-names></name><name><surname>Friedmann Angeli</surname> <given-names>JP</given-names></name><name><surname>Bayir</surname> <given-names>H</given-names></name><name><surname>Bush</surname> <given-names>AI</given-names></name><name><surname>Conrad</surname> <given-names>M</given-names></name><name><surname>Dixon</surname> <given-names>SJ</given-names></name><name><surname>Fulda</surname> <given-names>S</given-names></name><name><surname>Gascón</surname> <given-names>S</given-names></name><name><surname>Hatzios</surname> <given-names>SK</given-names></name><name><surname>Kagan</surname> <given-names>VE</given-names></name><name><surname>Noel</surname> <given-names>K</given-names></name><name><surname>Jiang</surname> <given-names>X</given-names></name><name><surname>Linkermann</surname> <given-names>A</given-names></name><name><surname>Murphy</surname> <given-names>ME</given-names></name><name><surname>Overholtzer</surname> <given-names>M</given-names></name><name><surname>Oyagi</surname> <given-names>A</given-names></name><name><surname>Pagnussat</surname> <given-names>GC</given-names></name><name><surname>Park</surname> <given-names>J</given-names></name><name><surname>Ran</surname> <given-names>Q</given-names></name><name><surname>Rosenfeld</surname> <given-names>CS</given-names></name><name><surname>Salnikow</surname> <given-names>K</given-names></name><name><surname>Tang</surname> <given-names>D</given-names></name><name><surname>Torti</surname> <given-names>FM</given-names></name><name><surname>Torti</surname> <given-names>SV</given-names></name><name><surname>Toyokuni</surname> <given-names>S</given-names></name><name><surname>Woerpel</surname> <given-names>KA</given-names></name><name><surname>Zhang</surname> <given-names>DD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease</article-title><source>Cell</source><volume>171</volume><fpage>273</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.09.021</pub-id><pub-id pub-id-type="pmid">28985560</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Study group</collab><name><surname>Walker</surname> <given-names>F</given-names></name><name><surname>Adamczyk</surname> <given-names>A</given-names></name><name><surname>Kellerer</surname> <given-names>C</given-names></name><name><surname>Belge</surname> <given-names>K</given-names></name><name><surname>Brück</surname> <given-names>J</given-names></name><name><surname>Berner</surname> <given-names>T</given-names></name><name><surname>Merten</surname> <given-names>K</given-names></name><name><surname>Núnez Gómez</surname> <given-names>N</given-names></name><name><surname>Neureither</surname> <given-names>M</given-names></name><name><surname>Röcken</surname> <given-names>M</given-names></name><name><surname>Ghoreschi</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Fumaderm in daily practice for psoriasis: dosing, efficacy and quality of life</article-title><source>The British Journal of Dermatology</source><volume>171</volume><fpage>1197</fpage><lpage>1205</lpage><pub-id pub-id-type="doi">10.1111/bjd.13098</pub-id><pub-id pub-id-type="pmid">24813676</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname> <given-names>LB</given-names></name><name><surname>Martinez-Garcia</surname> <given-names>E</given-names></name><name><surname>Nguyen</surname> <given-names>H</given-names></name><name><surname>Mullen</surname> <given-names>AR</given-names></name><name><surname>Dufour</surname> <given-names>E</given-names></name><name><surname>Sudarshan</surname> <given-names>S</given-names></name><name><surname>Licht</surname> <given-names>JD</given-names></name><name><surname>Deberardinis</surname> <given-names>RJ</given-names></name><name><surname>Chandel</surname> <given-names>NS</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The proto-oncometabolite fumarate binds glutathione to amplify ROS-dependent signaling</article-title><source>Molecular Cell</source><volume>51</volume><fpage>236</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2013.05.003</pub-id><pub-id pub-id-type="pmid">23747014</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tagaya</surname> <given-names>Y</given-names></name><name><surname>Wakasugi</surname> <given-names>H</given-names></name><name><surname>Masutani</surname> <given-names>H</given-names></name><name><surname>Nakamura</surname> <given-names>H</given-names></name><name><surname>Iwata</surname> <given-names>S</given-names></name><name><surname>Mitsui</surname> <given-names>A</given-names></name><name><surname>Fujii</surname> <given-names>S</given-names></name><name><surname>Wakasugi</surname> <given-names>N</given-names></name><name><surname>Tursz</surname> <given-names>T</given-names></name><name><surname>Yodoi</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Role of ATL-derived factor (ADF) in the normal and abnormal cellular activation: involvement of dithiol related reduction</article-title><source>Molecular Immunology</source><volume>27</volume><fpage>1279</fpage><lpage>1289</lpage><pub-id pub-id-type="doi">10.1016/0161-5890(90)90032-U</pub-id><pub-id pub-id-type="pmid">2177148</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname> <given-names>SX</given-names></name><name><surname>Greetham</surname> <given-names>D</given-names></name><name><surname>Raeth</surname> <given-names>S</given-names></name><name><surname>Grant</surname> <given-names>CM</given-names></name><name><surname>Dawes</surname> <given-names>IW</given-names></name><name><surname>Perrone</surname> <given-names>GG</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The thioredoxin-thioredoxin reductase system can function in vivo as an alternative system to reduce oxidized glutathione in Saccharomyces cerevisiae</article-title><source>Journal of Biological Chemistry</source><volume>285</volume><fpage>6118</fpage><lpage>6126</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.062844</pub-id><pub-id pub-id-type="pmid">19951944</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tse</surname> <given-names>HM</given-names></name><name><surname>Thayer</surname> <given-names>TC</given-names></name><name><surname>Steele</surname> <given-names>C</given-names></name><name><surname>Cuda</surname> <given-names>CM</given-names></name><name><surname>Morel</surname> <given-names>L</given-names></name><name><surname>Piganelli</surname> <given-names>JD</given-names></name><name><surname>Mathews</surname> <given-names>CE</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>NADPH oxidase deficiency regulates th lineage commitment and modulates autoimmunity</article-title><source>The Journal of Immunology</source><volume>185</volume><fpage>5247</fpage><lpage>5258</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1001472</pub-id><pub-id pub-id-type="pmid">20881184</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wakasugi</surname> <given-names>N</given-names></name><name><surname>Tagaya</surname> <given-names>Y</given-names></name><name><surname>Wakasugi</surname> <given-names>H</given-names></name><name><surname>Mitsui</surname> <given-names>A</given-names></name><name><surname>Maeda</surname> <given-names>M</given-names></name><name><surname>Yodoi</surname> <given-names>J</given-names></name><name><surname>Tursz</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Adult T-cell leukemia-derived factor/thioredoxin, produced by both human T-lymphotropic virus type I- and Epstein-Barr virus-transformed lymphocytes, acts as an autocrine growth factor and synergizes with interleukin 1 and interleukin 2</article-title><source>PNAS</source><volume>87</volume><fpage>8282</fpage><lpage>8286</lpage><pub-id pub-id-type="doi">10.1073/pnas.87.21.8282</pub-id><pub-id pub-id-type="pmid">2172979</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>JB</given-names></name><name><surname>Erickson</surname> <given-names>JW</given-names></name><name><surname>Fuji</surname> <given-names>R</given-names></name><name><surname>Ramachandran</surname> <given-names>S</given-names></name><name><surname>Gao</surname> <given-names>P</given-names></name><name><surname>Dinavahi</surname> <given-names>R</given-names></name><name><surname>Wilson</surname> <given-names>KF</given-names></name><name><surname>Ambrosio</surname> <given-names>AL</given-names></name><name><surname>Dias</surname> <given-names>SM</given-names></name><name><surname>Dang</surname> <given-names>CV</given-names></name><name><surname>Cerione</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Targeting mitochondrial glutaminase activity inhibits oncogenic transformation</article-title><source>Cancer Cell</source><volume>18</volume><fpage>207</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2010.08.009</pub-id><pub-id pub-id-type="pmid">20832749</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>R</given-names></name><name><surname>Dillon</surname> <given-names>CP</given-names></name><name><surname>Shi</surname> <given-names>LZ</given-names></name><name><surname>Milasta</surname> <given-names>S</given-names></name><name><surname>Carter</surname> <given-names>R</given-names></name><name><surname>Finkelstein</surname> <given-names>D</given-names></name><name><surname>McCormick</surname> <given-names>LL</given-names></name><name><surname>Fitzgerald</surname> <given-names>P</given-names></name><name><surname>Chi</surname> <given-names>H</given-names></name><name><surname>Munger</surname> <given-names>J</given-names></name><name><surname>Green</surname> <given-names>DR</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The transcription factor myc controls metabolic reprogramming upon T lymphocyte activation</article-title><source>Immunity</source><volume>35</volume><fpage>871</fpage><lpage>882</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2011.09.021</pub-id><pub-id pub-id-type="pmid">22195744</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>R</given-names></name><name><surname>Green</surname> <given-names>DR</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Metabolic checkpoints in activated T cells</article-title><source>Nature Immunology</source><volume>13</volume><fpage>907</fpage><lpage>915</lpage><pub-id pub-id-type="doi">10.1038/ni.2386</pub-id><pub-id pub-id-type="pmid">22990888</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Lu</surname> <given-names>H</given-names></name><name><surname>Wang</surname> <given-names>D</given-names></name><name><surname>Li</surname> <given-names>S</given-names></name><name><surname>Sun</surname> <given-names>K</given-names></name><name><surname>Wan</surname> <given-names>X</given-names></name><name><surname>Taylor</surname> <given-names>EW</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Inhibition of glutathione synthesis eliminates the adaptive response of ascitic hepatoma 22 cells to nedaplatin that targets thioredoxin reductase</article-title><source>Toxicology and Applied Pharmacology</source><volume>265</volume><fpage>342</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1016/j.taap.2012.09.001</pub-id><pub-id pub-id-type="pmid">22982619</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Q</given-names></name><name><surname>Chuikov</surname> <given-names>S</given-names></name><name><surname>Taitano</surname> <given-names>S</given-names></name><name><surname>Wu</surname> <given-names>Q</given-names></name><name><surname>Rastogi</surname> <given-names>A</given-names></name><name><surname>Tuck</surname> <given-names>SJ</given-names></name><name><surname>Corey</surname> <given-names>JM</given-names></name><name><surname>Lundy</surname> <given-names>SK</given-names></name><name><surname>Mao-Draayer</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Dimethyl fumarate protects neural stem/Progenitor cells and neurons from oxidative damage through Nrf2-ERK1/2 MAPK pathway</article-title><source>International Journal of Molecular Sciences</source><volume>16</volume><fpage>13885</fpage><lpage>13907</lpage><pub-id pub-id-type="doi">10.3390/ijms160613885</pub-id><pub-id pub-id-type="pmid">26090715</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinberg</surname> <given-names>SE</given-names></name><name><surname>Sena</surname> <given-names>LA</given-names></name><name><surname>Chandel</surname> <given-names>NS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mitochondria in the regulation of innate and adaptive immunity</article-title><source>Immunity</source><volume>42</volume><fpage>406</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2015.02.002</pub-id><pub-id pub-id-type="pmid">25786173</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willems</surname> <given-names>HL</given-names></name><name><surname>de Kort</surname> <given-names>TF</given-names></name><name><surname>Trijbels</surname> <given-names>FJ</given-names></name><name><surname>Monnens</surname> <given-names>LA</given-names></name><name><surname>Veerkamp</surname> <given-names>JH</given-names></name></person-group><year iso-8601-date="1978">1978</year><article-title>Determination of pyruvate oxidation rate and citric acid cycle activity in intact human leukocytes and fibroblasts</article-title><source>Clinical Chemistry</source><volume>24</volume><fpage>200</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">627049</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname> <given-names>J</given-names></name><name><surname>Meng</surname> <given-names>X</given-names></name><name><surname>Wancket</surname> <given-names>LM</given-names></name><name><surname>Lintner</surname> <given-names>K</given-names></name><name><surname>Nelin</surname> <given-names>LD</given-names></name><name><surname>Chen</surname> <given-names>B</given-names></name><name><surname>Francis</surname> <given-names>KP</given-names></name><name><surname>Smith</surname> <given-names>CV</given-names></name><name><surname>Rogers</surname> <given-names>LK</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Glutathione reductase facilitates host defense by sustaining phagocytic oxidative burst and promoting the development of neutrophil extracellular traps</article-title><source>The Journal of Immunology</source><volume>188</volume><fpage>2316</fpage><lpage>2327</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1102683</pub-id><pub-id pub-id-type="pmid">22279102</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>Y</given-names></name><name><surname>Dieter</surname> <given-names>MZ</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Shertzer</surname> <given-names>HG</given-names></name><name><surname>Nebert</surname> <given-names>DW</given-names></name><name><surname>Dalton</surname> <given-names>TP</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Initial characterization of the glutamate-cysteine ligase modifier subunit gclm(-/-) knockout mouse. novel model system for a severely compromised oxidative stress response</article-title><source>The Journal of Biological Chemistry</source><volume>277</volume><fpage>49446</fpage><lpage>49452</lpage><pub-id pub-id-type="doi">10.1074/jbc.M209372200</pub-id><pub-id pub-id-type="pmid">12384496</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zafarullah</surname> <given-names>M</given-names></name><name><surname>Li</surname> <given-names>WQ</given-names></name><name><surname>Sylvester</surname> <given-names>J</given-names></name><name><surname>Ahmad</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Molecular mechanisms of N-acetylcysteine actions</article-title><source>Cellular and Molecular Life Sciences</source><volume>60</volume><fpage>6</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1007/s000180300001</pub-id><pub-id pub-id-type="pmid">12613655</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zalkin</surname> <given-names>H</given-names></name><name><surname>Smith</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Enzymes utilizing glutamine as an amide donor</article-title><source>Advances in Enzymology and Related Areas of Molecular Biology</source><volume>72</volume><fpage>87</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">9559052</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname> <given-names>H</given-names></name><name><surname>Chi</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>mTOR signaling in the differentiation and function of regulatory and effector T cells</article-title><source>Current Opinion in Immunology</source><volume>46</volume><fpage>103</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2017.04.005</pub-id><pub-id pub-id-type="pmid">28535458</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname> <given-names>L</given-names></name><name><surname>Cardaci</surname> <given-names>S</given-names></name><name><surname>Jerby</surname> <given-names>L</given-names></name><name><surname>MacKenzie</surname> <given-names>ED</given-names></name><name><surname>Sciacovelli</surname> <given-names>M</given-names></name><name><surname>Johnson</surname> <given-names>TI</given-names></name><name><surname>Gaude</surname> <given-names>E</given-names></name><name><surname>King</surname> <given-names>A</given-names></name><name><surname>Leach</surname> <given-names>JD</given-names></name><name><surname>Edrada-Ebel</surname> <given-names>R</given-names></name><name><surname>Hedley</surname> <given-names>A</given-names></name><name><surname>Morrice</surname> <given-names>NA</given-names></name><name><surname>Kalna</surname> <given-names>G</given-names></name><name><surname>Blyth</surname> <given-names>K</given-names></name><name><surname>Ruppin</surname> <given-names>E</given-names></name><name><surname>Frezza</surname> <given-names>C</given-names></name><name><surname>Gottlieb</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Fumarate induces redox-dependent senescence by modifying glutathione metabolism</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>6001</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms7001</pub-id><pub-id pub-id-type="pmid">25613188</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.36158.028</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Dustin</surname><given-names>Michael L</given-names></name><role>Reviewing Editor</role><aff><institution>University of Oxford</institution><country>United Kingdom</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Dang</surname><given-names>Chi Van</given-names></name><role>Reviewer</role><aff><institution>University of Pennsylvania</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your article &quot;Glutathione denovo synthesis coordinates with glutaminolysis to control redoxhomeostasis &amp; directs Tcell differentiation&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by Tadatsugu Taniguchi as the Senior Editor, a Reviewing Editor, and three reviewers. The following individual involved in review of your submission has agreed to reveal his identity: Chi Van Dang (Reviewer #2).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>You have investigated the role of glutathione (GSH) de novo biosynthesis during T cell activation and differentiation. Using mouse genetic models, you found that GSH de novo synthesis plays a critical role in T<sub>H</sub>17 differentiation but is less important for T<sub>reg</sub> polarization. The defect in T<sub>H</sub>17 differentiation is due to the accumulation of ROS. Furthermore, loss of GSH reductase, the enzyme that reduces oxidized GSSG to GSH, does not have any effect on T cell differentiation. Finally, you have connected glutaminolysis, an important metabolic rewiring step in T cell differentiations, to GSH production. You have asked an interesting and important question and found an interesting answer to complement the discovery by Mak et al. (2017). These studies together elucidate the physiological role of glutathione synthesis in T cell differentiation. However, the reviewers felt there were still some conclusions that need to be strengthened for publication in <italic>eLife</italic>.</p><p>Essential revisions:</p><p>The reviewers would like to prioritize further data on how glutathione de novo biosynthesis/redox contributes to the biological effect of glutaminolysis in T cell differentiation:</p><p>1) Can you rescue T<sub>H</sub>17 differentiation or suppress T<sub>reg</sub> differentiation in the qlutamine free condition by mitigating the ROS through an anti-oxidant, such as NAC? Does pharmacological inhibition of the first step of glutaminolysis at glutaminase (via CB-839 or BPTES, which is documented to increase ROS) could skew away from T<sub>H</sub>17 toward T<sub>reg</sub> differentiation.</p><p>2) Can exogenous supply of other glutamine-derived metabolites (TCA cycle intermediate or nucleotide) rescue T<sub>H</sub>17 differentiation in glutamine-free condition without influencing the redox status?</p><p>3) In Figure 6B, you claimed a glutamine-dependent flux into GSH, but M+5 species is minimal compared to the other species, while glutamine depletion causes very profound defect in T<sub>H</sub>17 in Figure 6D. You need to show the levels of GSH during glutamine starvation and should be more careful about conclusions on the significance of glutamine-dependent GSH production on T<sub>H</sub>17 differentiation.</p><p>[Editors' note: further revisions were requested prior to acceptance, as described below.]</p><p>Thank you for sending your article entitled &quot;Glutathione de novo synthesis but not recycling process coordinates with glutaminolysis to control redox homeostasis and directs murine T cell differentiation&quot; for peer review at <italic>eLife</italic>. Your article is being evaluated by Tadatsugu Taniguchi as the Senior Editor, a Reviewing Editor, and three reviewers.</p><p>There was a diversity of opinion among reviewers and we invite you to respond within the next two weeks with an action plan and timetable to respond whether you will undertake below proposed revisions that require would appear to require new experiments within a two month period or do you disagree and prefer to move ahead with textual changes to address the essential and minor comments without new experiments. Based on your response we will then provide a decision letter. If you decide on the latter course it’s very likely the result will be acceptable, but the editors wanted to leave the former option open to you given that you may see it as an opportunity you don't want to miss.</p><p>Essential revisions:</p><p>The question regarding rescue of glutamine-deprived T<sub>H</sub>17 cells with NAC or with downstream metabolites was only partially addressed. While you showed that hypoxanthine and thymidine could partially rescue T<sub>H</sub>17 without altered ROS, NAC alone could not rescue the phenotype. You missed the opportunity of combining hypoxanthine, thymidine and NAC to test your hypothesis that ROS plays a critical role. Further, your experiments using CB839, BPTES, and DON were not accompanied by any ROS measurements. Specifically, according to the T<sub>H</sub>-Express database, in contrast to your assertion, Gls is expressed across murine T cell subsets. Hence, the lack of effects of specific Gls inhibitors seem surprising. DON is a non-specific glutamine analog that has pleiotropic effects. ROS measurements would help overcome these concerns.</p><p>1) Subsection “GCLC deficiency but not GCLM or GSR deficiency suppresses T cell activation and proliferation”, why the authors concluded &quot;T cells are relatively resistant toward ferroptosis&quot;, as I saw a modest reduction of viability.</p><p>2) Subsection “Glutamate that fuels GSH de novo synthesis is partially derived from glutamine during T<sub>H</sub>17 cell differentiation”, a simplest explanation of Figure 6B is that glutamine uptake in iT<sub>reg</sub> is significantly lower. But whatever glutamine that cells can uptake, contributes similarly to glutamate and GSH between T<sub>H</sub>17 and iT<sub>reg</sub>.</p><p>3) Subsection “Glutamate that fuels GSH de novo synthesis is partially derived from glutamine during T<sub>H</sub>17 cell differentiation”, I understand that the assay has been widely used, but the fundamental rationale behind it is unclear. Because the carbon dioxide released from glutamine is from α-ketoglutarate to succinyl-CoA, a step downstream of the glutamate. I think the experiment proves that glutaminolysis is more active in T<sub>H</sub>17 than iT<sub>reg</sub> but cannot further justify the contribution of glutamine oxidation to GSH production.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.36158.029</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>The reviewers would like to prioritize further data on how glutathione de novo biosynthesis/redox contributes to the biological effect of glutaminolysis in T cell differentiation:</p><p>1) Can you rescue T<sub>H</sub>17 differentiation or suppress T<sub>reg</sub> differentiation in the qlutamine free condition by mitigating the ROS through an anti-oxidant, such as NAC?</p></disp-quote><p>We are thankful for the reviewer’s thoughtful assessment and suggestion. We have performed the differentiation experiment to evaluate the effect of NAC on rescuing T<sub>H</sub>17 differentiation in glutamine free condition. We found that NAC treatment was incapable of rescuing T<sub>H</sub>17 differentiation (Figure 6—figure supplement 1F). NAC addition also failed to restore cell proliferation in the absence of glutamine as indicated by comparable low cell numbers in both groups (Figure 6—figure supplement 1G). On the other hand, our conclusion is that GSH de novo biosynthesis requires glutamine-derived glutamate as precursor and plays a critical role in regulating ROS homeostasis during T<sub>H</sub>17 cell differentiation. We apologize if we have given the unintended impression that GSH de novo biosynthesis is responsible for all essential functions of glutaminolysis. Other glutamine-derived metabolites, as the reviewer pointed out below, also play significant roles in driving T cell proliferation, maintaining cell viability and regulating T cell differentiation. We ensured that this is stated clearly in the text.</p><disp-quote content-type="editor-comment"><p>Does pharmacological inhibition of the first step of glutaminolysis at glutaminase (via CB-839 or BPTES, which is documented to increase ROS) could skew away from T<sub>H</sub>17 toward T<sub>reg</sub> differentiation.</p></disp-quote><p>We are thankful for the reviewer’s insightful suggestion. Glutaminase (GLS) (Altman et al. 2016) is a rate-limiting enzyme in glutamine catabolic pathway. Assessing the impact of GLS inhibitors in modulating T cell differentiation will not only provide mechanistic insights and also provide useful information that may have the potential to direct clinical application in the future. As the reviewer suggested, we have examined T<sub>H</sub>17 and iT<sub>reg</sub> differentiation in the presence of CB-839 or BPTES, two recently developed GLS inhibitors that preferentially inhibit GLS1 (Wang et al. 2010, Le et al. 2012). In addition, we also include 6-diazo-5-oxo-l-norleucine (DON), an analog of glutamine with broad inhibitory effects glutamine utilizing enzymes (Pinkus 1977, Shapiro et al. 1979), since our previous study indicated that GLS2 is significantly induced following T cell activation (Wang et al. 2011). Our results showed that DON treatment significantly suppressed T<sub>H</sub>17 cell differentiation (Figure 6—figure supplement 1D). Instead, BPTES or CB-839 treatment slightly enhanced IL-17A expression (Figure 6—figure supplement 1D). In line with these data, DON but not BPTES or CB-839 treatment significantly enhanced ROS production under T<sub>H</sub>17-polarizing condition (Figure 6—figure supplement 1E).</p><disp-quote content-type="editor-comment"><p>2) Can exogenous supply of other glutamine-derived metabolites (TCA cycle intermediate or nucleotide) rescue T<sub>H</sub>17 differentiation in glutamine-free condition without influencing the redox status?</p></disp-quote><p>We share a similar thought on the relevance of other glutamine-derived metabolites with the reviewers. Glutamine catabolism is not only coupled to the de novo synthesis of GSH, but also generates the anaplerotic substrate, α-ketoglutarate (α-KG), and substrates for nucleotide biosynthesis. As the reviewer pointed out, it is important to assess the contribution of α-KG and nucleotide in T<sub>H</sub>17 cell’s glutamine dependency. Therefore, we have supplied T cells with either α-KG and or hypoxanthine + thymidine (HT) under glutamine free condition and assessed T cell differentiation and ROS. Our data showed that the addition of either HT or α-KG was able to partially rescue T<sub>H</sub>17 differentiation in glutamine-free condition without impacting ROS level (Figure 6F and 6G). These results clearly demonstrated that other glutamine-derived metabolites, including nucleotides and α-KG contribute to T<sub>H</sub>17 cells’ glutamine dependency independent of ROS regulation. Again, we apologize if we have given the impression that GSH de novo biosynthesis is responsible for all essential functions of glutaminolysis. We ensured that this is stated clearly in the text.</p><disp-quote content-type="editor-comment"><p>3) In Figure 6B, you claimed a glutamine-dependent flux into GSH, but M+5 species is minimal compared to the other species, while glutamine depletion causes very profound defect in T<sub>H</sub>17 in Figure 6D. You need to show the levels of GSH during glutamine starvation and should be more careful about conclusions on the significance of glutamine-dependent GSH production on T<sub>H</sub>17 differentiation.</p></disp-quote><p>We apologize for giving the impression of overstating our data and have adjusted the text to properly explain our data. We also agree with the reviewer’s assessment on M+5 species data and appreciate the reviewer’s constructive comment on including GSH data following glutamine starvation. We have now included the data showing that, glutamine starvation reduced GSH content in a time-dependent manner in T<sub>H</sub>17 cells (Figure 6—figure supplement 1A). In addition, we have optimized the experimental conditions in assessing glutamine metabolic flux using <sup>13</sup>C-tracer. In addition, we have included iT<sub>reg</sub> cells group as a comparison of T<sub>H</sub>17 cells (Figure 6B). Our data revealed that T<sub>H</sub>17 cells displayed a higher capacity of funneling glutamine-derived carbons to glutamate and GSH than iT<sub>reg</sub> cells, as indicated by significantly elevated quantity of <sup>13</sup>C<sub>5</sub> labelled glutamate and GSH (Figure 6B, upper panel). Moreover, a significant portion of GSH pool comes from <sup>13</sup>C<sub>5</sub>-GSH, indicative of a direct conversion of <sup>13</sup>C-glutamine into GSH (Figure 6B, lower panel).</p><p>[Editors' note: further revisions were requested prior to acceptance, as described below.]</p><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>The question regarding rescue of glutamine-deprived T<sub>H</sub>17 cells with NAC or with downstream metabolites was only partially addressed. While you showed that hypoxanthine and thymidine could partially rescue T<sub>H</sub>17 without altered ROS, NAC alone could not rescue the phenotype. You missed the opportunity of combining hypoxanthine, thymidine and NAC to test your hypothesis that ROS plays a critical role. Further, your experiments using CB839, BPTES, and DON were not accompanied by any ROS measurements. Specifically, according to the Th-Express database, in contrast to your assertion, Gls is expressed across murine T cell subsets. Hence, the lack of effects of specific Gls inhibitors seem surprising. DON is a non-specific glutamine analog that has pleiotropic effects. ROS measurements would help overcome these concerns.</p></disp-quote><p>We thank the reviewers for the additional constructive comments. We took this opportunity to further strengthen our studies by performing additional experiments and properly interpreting our data.</p><p>Specifically,</p><p>1) We have assessed T<sub>H</sub>17differentiation in glutamine-starvation condition after adding HT and NAC either alone or in combination. While NAC alone is insufficient to support T<sub>H</sub>17differentiation (likely due to its incapability of supporting T cell proliferation in the absence of glutamine), the combination of NAC and HT resulted in more differentiated T<sub>H</sub>17cells and lower level of ROS comparing to HT alone in the absence of glutamine (Figure 6—figure supplement 1F and G). These results support the idea that glutamine catabolism supports T<sub>H</sub>17differentiation through providing precursors for supporting both proliferation and redox regulation.</p><p>2) For CB839, BPTES, and DON experiment, we have included original ROS data (Figure 6—figure supplemental 1E). We found that only DON treatment increases ROS production, which is in consistent with our T<sub>H</sub>17differentiation data (only DON suppresses T<sub>H</sub>17differentiation). Now, we include both histogram and bar-graph in our revised figure. We also thank the reviewer for pointing out the expression data of Gls1 extracted from T<sub>H</sub>-Express database. We apologize for giving the impression that Gls1 is not expressed in CD4<sup>+</sup> T cells. We agree with the reviewer’s assessment on the pleiotropic effects of DON. We now carefully revised our interpretation on the data. In addition to Gls1, we reasoned that Gls2 may compensate for the inhibition of Gls1. Gls2 is also expressed in all T cell subsets with the highest expression level in T<sub>H</sub>17subset based on T<sub>H</sub>-Express database, and the protein level of Gls2 has been shown to be induced following T cell activation (Wang, Dillon et al., 2011). We also speculated that other glutamine utilizing enzymes including amidotransferase could convert glutamine into glutamate and might be involved in supporting GSH biosynthesis in T cells.</p><disp-quote content-type="editor-comment"><p>1) Subsection “GCLC deficiency but not GCLM or GSR deficiency suppresses T cell activation and proliferation”, why the authors concluded &quot;T cells are relatively resistant toward ferroptosis&quot;, as I saw a modest reduction of viability.</p></disp-quote><p>We agree with the reviewer’s assessment and have rephrased our interpretation according to the suggestion.</p><disp-quote content-type="editor-comment"><p>2) Subsection “Glutamate that fuels GSH de novo synthesis is partially derived from glutamine during T<sub>H</sub>17 cell differentiation”, a simplest explanation of Figure 6B is that glutamine uptake in iT<sub>reg</sub> is significantly lower. But whatever glutamine that cells can uptake, contributes similarly to glutamate and GSH between T<sub>H</sub>17 and iT<sub>reg</sub>.</p></disp-quote><p>We thank the reviewer for this insightful comment and have now included the heightened glutamine update as a possible explanation of our data.</p><disp-quote content-type="editor-comment"><p>3) Subsection “Glutamate that fuels GSH de novo synthesis is partially derived from glutamine during T<sub>H</sub>17 cell differentiation”, I understand that the assay has been widely used, but the fundamental rationale behind is unclear. Because the carbon dioxide released from glutamine is from α-ketoglutarate to succinyl-CoA, a step downstream of the glutamate. I think the experiment proves that glutaminolysis is more active in T<sub>H</sub>17 than iT<sub>reg</sub> but cannot further justify the contribution of glutamine oxidation to GSH production.</p></disp-quote><p>We apologize for giving the impression of overstating our data and have adjusted the text to properly explain our data according to the reviewer’s comment. Specifically, we have now highlighted the possibility that the overall uptake and consumption of glutamine, including oxidation of glutamate through the TCA cycle and utilization of glutamate for GSH biosynthesis is enhanced in T<sub>H</sub>17 comparing to iT<sub>reg</sub> cells.</p><p>We thank the editor and all of the assigned reviewers for the time and effort involved in assessing our work, and we hope that the reviewer agrees that in addressing the concerns we have substantially improved our manuscript.</p></body></sub-article></article>